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1 INTRODUCTION 
1.1 The neurotransmitter γ-aminobutyric acid 
The γ-aminobutyric acid (GABA) is the most abundant inhibitory 
neurotransmitter in the mammalian central nervous system (CNS). Approximately 
20-50% of all central synapses are supposed to use GABA as a transmitter, depending 
on the brain region (Bloom and Iversen 1971; Young and Chu 1990; Sivilotti and Nistri 
1991; Halasy and Somogyi 1993). 
GABA is formed in vivo by a metabolic pathway referred to as the GABA shunt. 
The GABA shunt is a closed-loop process with the dual purpose of producing and 
conserving the supply of GABA. Glucose is the principal precursor for GABA 
production in vivo, although pyruvate and other amino acids also can act as precursors 
(Fig. 1). 
 
Fig. 1: Simplified schematic diagram of the major metabolic pathways linking glycolysis and 
tricarboxylic acid cycle (TCA or Krebs cycle) flux to the synthesis of neurotransmitters (Siegel et al. 
1999). 
The first step in the GABA shunt is the transamination of α-ketoglutarate, a 
Krebs cycle intermediate, to glutamic acid. Then the glutamic acid decarboxylase 
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(GAD) catalyses the decarboxylation of glutamic acid to form GABA (Awapara et al. 
1950; Roberts and Frankel 1950). The glutamic acid decarboxylase appears to be 
expressed only in cells that use GABA as a neurotransmitter (Siegel et al. 1999). 
GABA can then be metabolized by transamination to succinic semialdehyde, and 
further oxidized to succinic acid, which can re-enter the Krebs cycle (Fig. 2). 
 
Fig. 2: GABA shunt reactions are responsible for the synthesis, conservation and metabolism of 
GABA (Siegel et al. 1999). 
GABA is stored in vesicles close to the synaptic membrane and is released into 
the synaptic cleft in response to a Ca2+ dependent process after depolarization of the 
presynaptic membrane. In the synaptic cleft GABA affects receptors on the 
postsynaptic membrane. The re-uptake by presynaptic terminals or glia cells occurs via 
highly specific transmembrane transporters (Minelli et al. 1995) (Fig. 3). 
The neurotransmitter GABA acts by two different classes of receptors,  the 
GABAA and the GABAB receptors (Hill and Bowery 1981; Bowery et al. 1983; Bowery 
1993). GABAA receptorsare Cl
- channels and are stimulated by GABA, muscimol, and 
isoguvacine, and are inhibited either competitively by bicuculline or non-competitively 
by picrotoxin and TBPS (t-butylbicyclophosphorothionate) (Macdonald and Olsen 
1994)) (Fig. 4). GABAB receptors are stimulated by GABA and (-)baclofen and are 
inhibited by phaclofen (Hill and Bowery 1981). The latter receptors seem to be coupled 
indirectly via an intervening G-protein or a second messenger system to Ca2+ and K+ 
channels (Bormann 1988; Bowery 1993) (Fig. 4). 
Other GABA receptors, the GABAC receptors, are stimulated by GABA and 
certain conformationally restricted analogues of GABA, such as cis-4-aminocrotonic 
acid (CACA). This class of receptors is insensitive to both bicuculline and (-)baclofen 
(Johnston 1994; Bormann and Feigenspan 1995; Johnston 1996). Since these 
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receptors are formed by ρ subunits that are homologous to GABAA receptor subunits it 
was decided that they should be classified as a subgroup of GABAA receptors (Barnard 
et al. 1998). 
 
Fig. 3: Schematic representation of a GABAergic synapse (Suzdak and Jansen 1995). 
 
 
Fig. 4: GABAA and GABAB receptor types. Direct gating of ionotropic GABAA receptors (A1, A2). Indirect 
gating of metabotrobic GABAB receptors. This is mediated by a second messenger that couples the 
GABAB receptor to the ion channel (B1, B2). The transmembrane structure of GABAA or GABAB receptor 
subunits is indicated in A2 or B2, respectively (Kandel et al. 1991). 
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1.2 Pharmacology of GABAA receptors 
GABAA receptors are ligand gated ion channels that can be opened by GABA 
and are the major inhibitory neurotransmitter receptors in the CNS (Macdonald and 
Olsen 1994). If GABA binds to the GABAA receptor, the neuronal membrane 
conductance for chloride ions increases. In most cases the intracellular chloride ion 
concentration is low and the extracellular concentration is high. Therefore the chloride 
gradient across the membrane forces chloride into the cell. 
At the resting membrane potential, however, this effect is more or less balanced 
by the electrochemical driving force that inhibits chloride entry because of the negative 
charge inside of the cell. Opening of chloride ion channels in unexcited neurons, thus, 
usually results in a slight membrane hyperpolarization and in a reduced neuronal 
excitability of the cells, because the increased chloride ion conductance counteracts 
the effects of depolarizing stimuli (Bormann 1988). 
In some cases, however, excitatory actions of GABA have been demonstrated. 
This unusual effect was demonstrated in developing brain tissue (Cherubini et al. 
1991), in some neurons from adult brain (Avoli 1992), in astrocytes and 
oligodendrocytes (von Blankenfeld and Kettenmann 1991), generally in cells 
possessing a high intracellular chloride ion concentration. The chloride gradient across 
the membrane of the respective cells is thus much smaller than in cells where GABA 
exerts a hyperpolarizing action. On opening of chloride ion channels, the 
electrochemical driving force pushes chloride ions out of the cell and this results in a 
depolarization of the membrane potential. 
Not only GABA is able to bind and thereby modulate the GABAA receptor but 
also many different drugs. Thus, benzodiazepines, barbiturates, steroids, anaesthetics, 
convulsants, or drugs that cannot be summarized into groups, like loreclezole (Sieghart 
1995), modulate the action of GABA by interacting with distinct allosteric binding sites 
on GABAA receptors. 
Thus binding studies and electrophysiological and behavioral experiments 
indicate that the anxiolytic, anticonvulsant, muscle relaxant and sedative-hypnotic 
benzodiazepines, and some depressant barbiturates enhance the action of GABA on 
GABAA receptors. In contrast, some anxiogenic or convulsant β-carbolines, the 
convulsants bicuculline, picrotoxin, or t-butylbicyclophosphorothionate (TBPS) reduce 
the actions of GABA on this receptor. Binding of such substances induces a 
conformational change in the GABAA receptors that in turn influences the binding 
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properties of other binding sites present on these receptors (causing complex allosteric 
interactions of these binding sites) and modulates GABA-induced chloride ion fluxes 
(Sieghart 1995). 
Based on their pharmacological action it was concluded that GABAA receptors 
are involved in controlling the excitability of the brain (Olsen and Avoli 1997; Fritschy et 
al. 1999), in the modulation of anxiety (Nutt 1990; Pratt 1992), of feeding and drinking 
behaviour (Cooper 1989), circadian rhythms (Turek and Van Reeth 1988), cognition, 
vigilance, memory and learning (Sarter et al. 1988; Izquierdo and Medina 1991). 
1.3 Molecular structure of GABAA receptors 
GABAA receptors are hetero-oligomeric receptors belonging to the super-family 
of ligand gated ion channels (Schofield et al. 1987), like the nicotinic acetylcholine 
(nAch), the glycine and the 5-HT3 receptors (Betz 1990; Ortells and Lunt 1995). The 
receptor is a pentamer (Nayeem et al. 1994; Tretter et al. 1997) and each of the five 
subunits comprises a large extracellular N-terminal domain, four transmembrane (TM) 
domains and a large intracellular loop between TM3 and TM4. The second 
transmembrane domain (TM2) is gating the ion channel pore (Fig. 5). 
So far six α, three β, three γ, one δ, one ε, one π, one θ, and three ρ subunits 
have been cloned and sequenced from the mammalian brain (Barnard et al. 1998; 
Bonnert et al. 1999). Immunohistochemical studies showed a distinct and often 
widespread distribution for each GABAA receptor subunit throughout the brain (Fritschy 
et al. 1998; Pirker et al. 2000). The resulting expression of multiple subunits in the 
same neurons suggests the existence of a large variety of GABAA receptors in the 
brain. Subunits, however, seem to combine only in specific combinations determining 
both the pharmacological and the electrophysiological property of this respective 
GABAA receptor (Sieghart 2000). 
Recently, a subtractive purification method was established, which allows the 
determination of the subunit composition of the native GABAA receptor subtypes 
(Jechlinger et al. 1998; Bencsits et al. 1999). Combined with studies investigating the 
subunit stoichiometry (Tretter et al. 1997), results indicated that the majority of GABAA 
receptors comprise two α, two β and one γ subunit (Sieghart et al. 1999) (Fig. 6). 
Investigations indicate that the γ subunit can be substituted by the δ, ε, or π 
subunit (Shivers et al. 1989; Hedblom and Kirkness 1997; Whiting et al. 1997) and the 
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β subunit by the θ one (Whiting 1999) (Fig. 6). In contrast the ρ subunits seem to form 
only homo- or hetero-oligomeric receptors with other ρ subunits, forming the previously 
described ―GABAC‖ receptors (Johnston 1994; Bormann and Feigenspan 1995; 
Johnston 1996). 
 
Fig. 5: Schematic model for the topology of the GABAA receptor in the cell membrane. Four 
transmembrane domains in each subunit are shown as cylinders. The structure in the extracellular domain 
is drawn in an arbitrary manner and shows the cys-loop formed by the disulfide bond predicted at the 
conserved cysteines. Potential extracellular sites for N-glycosylation are indicated by triangles. Those 
charged residues, which are located within or close to the ends of the membrane domains, are indicated in 
small circles with charge marked. An encircled P marks the site for cAMP-dependent serine 
phosphorylation, present only in the β subunit (Schofield et al. 1987). 
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Fig. 6: Molecular structure of GABAA receptors (Jacob et al. 2008). 
1.4 Trafficking of GABAA receptors 
GABAA receptors subunits are synthesized and assembled in the endoplasmic 
reticulum (ER). These processes can be modulated by ubiquitylation and subsequent 
ER-associated degradation by the proteasome. Ubiquitylated GABAAR subunits can 
also be modulated by their association with PLIC1. PLIC1 facilitates GABAAR 
accumulation at the synapse by preventing the degradation of ubiquitylated GABAARs. 
The traffic into the Golgi network and subsequent trafficking to the plasma membrane 
are also facilitated by a number of GABAAR-associated proteins (GABARAP). These 
proteins associate with the γ2 subunit. N-ethylmaleimide-sensitive factor (NSF) and 
brefeldin-A-inhibited GDP/GTP exchange factor 2 (BIG2) bind to the β subunits and 
modulate GABAAR trafficking in the Golgi. There the palmitoylation of γ subunits takes 
place as a result of an association with the palmitoyltransferase Golgi-specific DHHC 
zinc-finger-domain protein (GODZ), and it is a critical step in the delivery of GABAARs 
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to the plasma membrane. GABAAR -interacting factor proteins (GRIFs) and 
Phospholipase-C-related catalytically inactive proteins (PRIPs) play an important role 
during the trafficking of GABAARs to the membrane and the phosphorylation state of 
GABAARs (Chen et al. 2007; Jacob et al. 2008) (Fig. 7). 
 
Fig. 7: GABAA receptor trafficking in the cell (Jacob et al. 2008). 
1.5 Recombinant protein expression systems 
In basic research and in terms of large-scale production of recombinant proteins 
the expression of foreign genes in diverse host organisms has become particularly 
interesting. The usage of classical approaches with yeast and E.coli as expression 
hosts has been extended by insect cell and mammalian cell expression systems in the 
last years. 
The insect cell and mammalian cell expression systems show huge advantages 
compared to yeast and E.coli. Expressed recombinant proteins show essential 
posttranslational modifications (PTM) such as glycosylation (by cell specific enzymes 
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like glucosidases, mannosidases and N-acetylglucosamine.transferases), 
phosphorylations, carboxylation and fatty acid acylation. In addition there is a controlled 
signal and proteolytic cleavage, which are necessary for proper folding and function of 
foreign proteins. Tab. 1 shows a comparison of the different recombinant protein 
expression systems. 
 
Tab. 1: Comparison of different recombinant protein expression systems.  PTM = posttranslational 
modifications (http://www.genwaybio.com). 
1.6 Baculovirus expression vector system 
Over the past 25 years the baculovirus-insect cell expression system has 
become one of the most widely used systems for routine production of recombinant 
proteins. A number of technological improvements have eliminated the original tedious 
procedures required to identify and isolate recombinant viruses, increasing the 
popularity of the system. These include development of a wide variety of transfer 
vectors, simplified recombinant virus isolation and quantification methods, advances in 
cell culture technology and the commercial availability of reagents. These 
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enhancements have resulted in a virus-based expression system that is safe, easy to 
use and readily amenable to scale-up (Kost et al. 2005; Jarvis 2009). 
Baculoviruses make up a family of viruses and are grouped into nuclear 
polyhedrosis viruses (NPV) and granulosis viruses. More then 500 different types of 
baculoviruses have been discovered and the host range is restricted to invertebrates, 
mostly to insects (eg, moths and butterflies)(Hu 2005). 
Among the numerous baculoviruses, Autographa californica multiple NPV 
(AcMNPV) is the most well studied and most extensively used. AcMNPV has a circular 
double-stranded DNA genome of approximately 130kbp (Blissard and Rohrmann 
1990). 
The DNA is condensed with a protamine –like protein into the core and packed 
into the nucleocapsides. Nucleocapsides are synthesized in the nucleus of infected 
cells (typically 40nm-50nm in diameter and 200nm-400nm in length). 
Membrane-enveloped Nucleocapsides are referred to as virus particles or virions. In 
nature, AcMNPV are occluded in a polyhedron (2µm-15µm in size) mainly consisting of 
polyhedron protein. After ingestion by insects, the polyhedron matrix is dissolved in the 
alkaline midgut, thus releasing the embedded virions, which subsequently infect 
epithelial cells of the intestine. Early in the infection cycle, the DNA genome is 
replicated and transcribed in the nucleus and the nucleocapsides are assembled. (Hu 
2005). 
 
Fig. 8: Electron micrograph of a baculovirus 
(http://www.mardre.com/homepage/mic/tem/samples/bio/virus/bac2.htm). 
In the infected cell the expression of polyhedron protein is confined to the late 
stages of the infection cycle (15-96h post-infection), after production of the virus 
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particles which spread the infection to other cells. The polyhedron protein accumulates 
to very high levels within the infected cell and has been variously estimated to account 
for 20-50% of the total cell associated protein by the end of the virus replication cycle. 
Polyhedrin gene deletion mutants of AcMNPV produce infectious virus particles but not 
polyhedron inclusion bodies. This feature of the virus allowed the substitution of foreign 
genes in place of the polyhedron and their expression to high levels in cells infected 
with the recombinant viruses (Possee and Howard 1987). Viral budding and infection of 
new cells through adsorptive endocytosis are mainly triggered by the virus-coded 
glycoprotein gp64 which plays a key role in the baculoviral life cycle. This protein forms 
trimers and accumulates at the poles of the capside giving it its characteristic 
morphology (Whitford et al. 1989). 
Several hundred different genes of viral, animal and herbal origin have already 
been expressed successfully using the baculovirus expression system. Expression 
yields can reach as much as 500mg per litre culture volume taking advantage of the 
very strong polyhedron and p10 promoters. Moreover, the separation of virus 
production and foreign gene expression with these very late promoters facilitates the 
production of possibly cytotoxic proteins as shown by Baum et al. (Baum et al. 1987). 
The most commonly used insect cell lines are the Sf9 and the Sf21 cell lines. 
They both originated from IPLB (USDA Insect Pathology Laboratory at Beltsville, 
Maryland). They are derived from Spodoptera frugiperda pupal ovarian tissue. They 
grow at a doubling time of approximately 18-22 hours in both, monolayer and 
suspension culture. Cells can be propagated in serum-supplemented media as well as 
in serum-free media (Vaughn et al. 1977). 
Insect cells are capable of performing many of the posttranslational 
modifications necessary for the production of functionally active proteins. It is equally 
true that insect protein processing pathways are not necessarily equivalent to those of 
higher eukaryotes. Most baculovirus-expressed recombinant glycoproteins will acquire 
authentic N-glycans only at sites occupied by high mannose structures on the native 
mammalian products. In contrast, they are most likely acquired paucimannose 
N-glycans at sites occupied by complex, terminally galactosylated and/or sialylated 
N-glycans on the native product (Fig. 9) (Kost et al. 2005). 
All the advantages and the high working safety make the baculovirus 
expression system to a valuable and recommendable tool for the production of 
complex proteins, especially for applications in biomolecular research and medicine 
(Massotte 2003). 
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Fig. 9: Overview of processing pathways and major N-glycans produced by insect and mammalian 
cell systems. The processing pathways in both systems yield common intermediate. The major insect-cell 
end product (paucimannose) is produced by further trimming of this intermediate (left-hand branch), 
whereas the major mammalian-cell and products (including sialyted complex) are produced by elongation 
of this intermediate (right-hand branch) (Kost et al. 2005). 
1.7 Scope of work 
GABAA receptors are targets for many clinically important drugs (Sieghart 1995) 
that influence excitability of the brain, motor function, anxiety, cognition, vigilance and 
memory. The exact molecular structure of the GABAA receptor is still unknown, as it is 
the case for most receptors of the cys-loop receptor super-family.  
The structural analysis of GABAA receptors by crystallization or NMR 
techniques requires high amounts of pure receptors. The aim of this thesis is to 
produce recombinant hetero-oligomeric (alpha1-beta3-gamma2) GABAA receptors. 
These receptors will be expressed in the baculovirus expression system, characterized 
and then further investigated together with collaborating international groups. 
This thesis is based on the thesis ―High yield expression and His-tag purification 
of recombinant GABAA receptors using the Sf9-baculovirus Expression Vector System‖ 
from Leila Wabenegger, 2005. Produced and characterized virus stocks from the latter 
thesis were taken to produce new virus stocks or to start other expression experiments. 
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2 MATERIALS AND METHODS 
2.1 Cloning 
2.1.1 Plasmid DNA preparation 
2.1.1.1 DNA Miniprep 
For the purification of small amounts of DNA the QIAprep® Miniprep Kit 
(QIAGEN) was used. Therefore 20ml of LB-medium, containing 100µg/ml ampicillin, 
were inoculated with a single colony of Escherichia coli XL-1-Blue cells (Stratagene) 
transformed with a pCI, pUC18 or a pBAC 4x-1 vector. The cells were grown over night 
and 5ml of the culture were harvested. 
LB-medium 10g Bactotryptone 
5g Yeast extract 
5g NaCl 
ddH2O to a total volume of 1000ml 










50mM Tris-Cl, pH 8.0 
10mM EDTA 
100µg/ml RNAse A 
200mM NaOH 
1% SDS (w/v) 
QIAGEN® 
QIAGEN® 
10mM Tris-HCl pH 8.5 
The pellet was resuspended in 250µl buffer P1, transferred into a sterile 1.5ml 
Eppendorf tube and 250µl of lysis buffer P2 were added. The tube was inverted gently 
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4-6 times and incubated for 5min at room temperature. After addition of 350µl buffer N3 
the tube was inverted 4-6 times and centrifuged for 10min at 15,700 x g. 
The clear supernatant was applied to a QIAprep® spin column and centrifuged 
for 1min 15,700 x g at room temperature. The column was washed with 750µl buffer 
PE and centrifuged twice at 15,700 x g for 1 min. Then the column was transferred to a 
1.5ml Eppendorf tube. The DNA was eluted with 75µl buffer EB (centrifugation: 1min, 
15,700 x g, room temperature) and was stored at 4°C. 
2.1.1.2 DNA Maxiprep (Endofree) 
For subsequent transfection of Sf9 cells, plasmid DNA of high purity is 
essential. Therefore, the DNA was purified using the Endofree Plasmid® Maxi Kit 
(QIAGEN) according to the kit manual. 
5ml of LB-medium containing 50µg/ml ampicillin were inoculated with a single 
colony and grown in a shaking incubator for 6 hours at 37°C. The starter culture was 
diluted with 400ml LB-medium including 50µg/ml ampicillin. The cells were grown at 
37°C for 12-16 hours and harvested at an OD600 of 1.5 - 1.8 (centrifugation: 15min, 
4,600 x g, 4°C). The dry pellet was stored at -20°C until usage. 
After thawing, the pellet was resuspended in 20ml buffer P1 (4°C). Then 20ml of 
buffer P2 were added, the solution was mixed gently and incubated for 5min at room 
temperature. After adding 20ml cold buffer P3, the lysate was incubated for 10min at 
4°C and centrifuged (30min, 48,000 x g, 4°C). The clear supernatant (lysate) was 
transferred to a fresh tube, 5ml of ER buffer were added and the solution was 
incubated for 30min at 4°C. 
A QIAGEN-tip 100 was equilibrated with 4ml buffer QBT and the lysate applied 
to it. The column was washed twice with 10ml buffer QC and the DNA was eluted with 
5ml buffer QN. The DNA was precipitated with 3.5ml Isopropanol and centrifuged for 
60min at 4,600 x g 4°C. The DNA pellet was washed with 2ml endotoxin-free 70% 
ethanol and centrifuged again (60min, 4,600 x g, 4°C). The DNA pellet was air dried 
and redissolved in 200µl buffer TE for 15min at 65°C. The DNA was then stored at 4°C. 
2.1.2 Determination of DNA concentration by optical 
density measurement 
The DNA concentration and quality were determined by measuring with a UV 
spectrometer (Hitachi U-2001). 
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450µl of a 1:30 dilution in ddH2O of the DNA sample were prepared and 
transferred into a quartz cuvette. Double-distilled water was measured as a reference 
to subtract the background absorbance from the sample data. The concentration was 
calculated as described below: 
C (µg/ml) = OD260 x dilution x 50µg/ml 
The DNA purity was estimated by the ratio between OD260 and OD280 
2.1.3 DNA digestion with restriction enzymes 
The digestion of DNA with restriction enzymes is necessary to prepare vector 
and insert for the ligation step. Enzymes and 10x reaction buffers were supplied from 
Roche Diagnostics and Promega. 
The DNA was incubated with restriction endonucleases in the appropriate buffer 
at the optimum temperature for the enzymes for 1-16 hours. To purify the DNA 
fragments, an agarose gel electrophoresis was performed and the fragments were cut 
out under UV illumination. Vectors and digested PCR fragments were purified by using 
the GFX PCR and Gel Band Purification Kit (2.1.5.2). 
2.1.4 Agarose gel electrophoresis 
Agarose gel electrophoresis is used to separate DNA by their size. The agarose 
concentration of the gel was chosen depending of expected length of DNA fragments: 
1.0-10.0kbp:  0.8-1.0% Agarose 
0.2-2.0kbp:  1.5-2.5% Agarose 
For a 1% mini-gel (10x6.5cm), 0.5g agarose (Life Technologies) were added to 
50ml 1xTBE buffer and heated in a microwave. After cooling to 50-55°C, 2.5µl 
ethidiumbromide (10mg/ml) were added. The gel was poured and was allowed to form 
completely at 4°C. The samples, mixed with 10x loading buffer, were loaded into the 
wells. After loading a DNA ladder, the gel was run at 8-10 V/cm. The DNA fragments 
were visualized under UV light and photographed. 
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10x TBE buffer 900mM Tris 
900mM Boric acid 
25mM EDTA 
 
10x Loading buffer 7.5g Ficoll 
0.01g Xylencyanol EF42 
2ml 0.5M EDTA 
pH 8.0 
total volume of 25ml with MilliQ 
2.1.5 Purification of DNA fragments 
DNA fragments from PCR or agarose gel fragments were purified with the GFX 
PCR DNA and Gel Purification Kit from GE Healthcare (capture buffer, washing buffer, 
EB buffer). Using this method, primer, salts and other contaminations were eliminated 
quantitatively. 
2.1.5.1 Purification of DNA fragments in solutions 
A maximum of 100µl sample was mixed with 500µl capture buffer, applied on a 
GFX Microspin™ column, incubated for 1min and centrifuged at 15,700 x g for 30sec. 
The column was washed with 500µl washing buffer and centrifuged for 90sec at 
15,700 x g. Then the column was transferred to a 1.5ml Eppendorf tube. To elute the 
DNA 15-50µl elution buffer EB were dropped on the filter in the column, incubated for 
60sec at room temperature and centrifuged for 60sec at 15,700 x g. 
2.1.5.2 Purification of DNA fragments from agarose gel 
For every 100mg of agarose gel slice 100µl capture buffer were added and 
incubated at 60°C in a Thermomixer until the agarose was dissolved completely. The 
mixture was loaded onto a GFX Microspin column. The column was centrifuged, 
washed and DNA eluted as described in 2.1.5.1. 
2.1.6 Ligation of DNA 
For the ligation of a vector and an insert the Rapid DNA ligation Kit (Roche) was 
used. A molar ratio of the vector DNA to insert DNA should be between 1:1 to 1:5. 
Materials and methods  Katharina Grote 
 25 
Ligation mix 2-4ng Vector DNA 
10ng Insert DNA 
1µl 5x DNA dilution buffer (Roche) 
5µl 2x DNA ligation buffer (Roche) 
3U T4 DNA ligase (Roche) 
ddH2O to 10µl total volume 
 
The reaction mix was incubated for 30min at room temperature and used 
immediately for transformation (2.1.7). 
2.1.7 Transformation 
2.1.7.1 XL1-Blue competent cells 
Competent Escherichia coli XL1-Blue cells were prepared in our lab and 
aliquots were frozen at -80°C. For transformation 100µl of XL1-Blue competent cells 
were thawed at room temperature, mixed with 8µl of the ligation reaction (see 2.1.6) 
and were incubated on ice for 30min. After heat shock (90sec at 42°C, water bath), the 
cells were incubated for 2min on ice and 400µl of SOC, pre-warmed to 42°C, were 
added. Then this suspension was incubated for 60min at 37°C and 50-200µl were 
plated on LB-plates with 50 or 100µg/ml ampicillin, respectively. The plates were 
incubated over night at 37°C. 
SOB medium 10g Bactotryptone 
2.5g Yeast extract 
290mg NaCl 
95mg KCl 
dH2O to a total volume of 500ml 
Sterilized by autoclaving 
5ml 2M MgCl2 (sterile) were added before 
use 
SOC medium 10ml SOB medium 
100µl 2M Glucose (sterile) 
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2.1.7.2 XL1-Blue supercompetent cells (Stratagene) 
Supercompetent Escherichia coli XL1-Blue cells (Stratagene) were thawed on 
ice. 100µl were transferred into a pre-cooled, sterile Falcon 2059 tube. After addition of 
1.7µl 1.42M β-mercaptoethanol, the tube was incubated for 10min on ice with gently 
shaking every 2 minutes. 2-4µl of the ligation mix (see 2.1.6) were added and the cells 
incubated for 30min on ice and heat shocked for 45-50sec at 42°C in the water bath. 
The cells were incubated for 2min on ice and 900µl SOC, pre-warmed to 42°C, were 
added. Then this suspension was incubated for 60min at 37°C and 50-200µl were 
plated on LB-plates with 50 or 100µg/ml ampicillin, respectively. The plates were 
incubated over night at 37°C. 
2.1.7.3 Long term storage of bacteria 
From each positive clone 500µl of the bacterial overnight culture were 
transferred into a 2ml microcentrifuge tube and mixed with 500µl glycerol freezing 
solution and stored at -80°C 
Glycerol freezing solution (30ml) 22.5ml Glycerol 87% (sterile) 
3.75ml MilliQ 
750µl 1M Tris HCl, pH 8.0 
3ml 1M MgSO4 
2.1.8 Polymerase Chain Reaction 
The polymerase chain reaction (PCR) is a technique to amplify a selected 
sequence of a DNA template using specifically designed primers and a thermostable 
DNA polymerase. 
2.1.8.1 In vitro Mutagenesis, Gene SOEing 
Gene SOEing stands for gene splicing by overlapping extensions (Horton et al. 
1990; Horton 1997). This is a PCR based approach to introduce mutations or tags into 
a gene sequence. 
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Example: Mutation of the alpha1 subunit 
The BamHI restriction site between the transmembrane domain 3 and 4 of the 
alpha1 subunit gene was deleted (silent mutation). This mutation was necessary to 
avoid a cleavage of the alpha1 subunit gene during subsequent cloning steps. 
The construct α1pCI was used as a template for generating two PCR-fragments 
containing the silent mutation (BamHI restriction site deleted). PCR product 1 (primer 
pair alpha1-Bcl-F and alpha1-mut-R3, 1130bp) and PCR product 2 (primer pair 
alpha1-mut-F3 and pCi-R3, 460bp) were mixed and used as template for the third PCR 
performed with the primer pair alpha1-Bcl-F and pCi-R3 (1558bp). The resulting PCR 
product was digested with the enzymes BclI and EcoRI and ligated into the BglII and 























Fig. 10: Schematic drawing of Gene SOEing. Three PCR steps were necessary to delete the BamHI 
restriction site between the transmembrane domain 3 and 4 of the alpha1 construct. This was performed 
by introducing a silent mutation in the overlapping primer sequences. The resulting third PCR product was 
digested with the enzymes BclI and EcoRI and ligated into the BglII and EcoRI digested modified pUC18 
vector. 
2.1.8.2 PCR screening of recombinant DNA clones 
Well isolated single colonies were picked from agar plates and resuspended in 
80µl ddH2O. 40µl of this suspension were transferred into 500µl LB-medium containing 
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the required antibiotic and incubated at 37°C in a Thermomixer (Eppendorf). The 
remaining 40µl were denatured (5min at 95°C and 5min on ice) and centrifuged at 
15,700 x g for 2min at room temperature. 5µl of the denatured DNA were used for 
screening PCR. As a positive control 0.5µl of the ligation mix were used. As a negative 
control 5µl ddH2O instead of DNA were used. 
PCR reaction mix (4 samples) 10µl 10x buffer QIAGEN 
8µl dNTP mix (2.5mM each) 
2µl Primer A (10pmol/µl) 
2µl Primer B (10pmol/µl) 
0.4µl Taq DNA polymerase (5U/µl 
QIAGEN) 
57.6µl MilliQ to a total of 80µl 
+5µl denatured DNA to 20µl mix 






The PCR product was analyzed by agarose gel electrophoresis. 
Positive clones were selected for plasmid DNA preparation. For an overnight 
culture 20ml LB medium containing the appropriate antibiotic were inoculated with 20µl 
of positive clone suspension and incubated at 37°C on a shaking incubator. Plasmid 
DNA was purified as described in 2.1.1.1 and sequenced (VBC-Biotech, Vienna). 
2.2 Insect cell culture 
2.2.1 Cultivation of Sf9 insect cells 
Sf9 cells were grown in serum-free InsectXpress medium (LONZA). For 
maintaining the cell line, Sf9 cells were cultivated in cell culture flasks (Nunclon, VWR) 
at 27°C (Incubator Type B 6120, Heraeus). They were seeded at 0.45 x 106 cells/ml 
and passaged when reaching a confluent layer (usually after 3 to 4 days). Adherently 
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grown cells were detached from the surface by shaking the flasks or by repeated 
aspiring with the pipette. 
For mid scale production and infection of cells, the Sf9 cells were grown as 
suspension cultures in InsectXpress medium, containing an antibiotic mixture (100U/ml 
Penicillin, 100U/ml Streptomycin and 0.25µg/ml Amphotericin, Lonza, Walkersville, MD 
USA). Cells were cultivated in sterile Erlenmeyer flasks (Corning) in a shaking 
incubator (Multitron II, INFORS AG) at 27°C and 140rpm. 
Cells were grown to a cell density of about 3.0 x 106 cells/ml and diluted to 
0.45 x 106 cells/ml every 2 to 3 days. The density of the cells was determined with a 
―Neubauer improved‖ counting chamber (Marienfeld). The viability of the cells was 
determined by mixing the cells with 0.4% Trypan Blue-solution (GIBCO). Trypan Blue 
can only be accumulated by dead cells and thus dead cells appear violet and can be 
counted when visualized in a microscope. 
For infection, cells were used at a density of 2-2.5 x 106 cells/ml and 5% fetal 
calf serum (FCS) were added to the InsectXpress medium to slow down degradation of 
the viruses by proteases. The cells were harvested two to three days post infection 
(4,600 x g, 15min, 4°C). The cell pellets were stored at -80°C for further experiments, 
like Western blot analysis (2.6.1), radioligand binding assays (2.3) or receptor 
purification experiments (2.4, 2.5). 
For long-term storage log-phase Sf9 cells (~80% confluent layer) were 
harvested (2,000 x g, 5min, 4°C) and resuspended and diluted in freezing medium 
(InsectXpress + 15% DMSO, 4°C) to an end concentration of about 1-2 x 107 cells/ml. 
Cells were transferred to freezer vials and after slow freezing stored in liquid nitrogen. 
Usually, Sf9 cells were substituted by freshly thawed cells after passage 35 (after about 
3 month). 
Sf9 cells were thawed by placing the vial directly into a water bath at 37°C for 
about 2 minutes. The content of the vial was then transferred into a Nunc tissue culture 
flask containing 10ml of InsectXpress medium. Cells were allowed to settle for 30 
minutes at room temperature and afterwards incubated at 27°C. After 4 hours the 
medium and floating cells were drawn off and 10ml of fresh medium were added to the 
flask and incubation at 27°C continued. When cells became ~90% confluent, 
monolayer culture was split 1:3 and after one to two weeks normal culturing (1:10) 
could be continued. 
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2.2.2 Transfection of Sf9 cells to produce recombinant 
viruses 
To produce recombinant baculoviruses, Sf9 cells were co-transfected with 
transfer plasmid DNA and Bac Magic™ DNA (Novagen). 
For each co-transfection 2ml Sf9 cells in BacVector Insect Cell Medium 
(Novagen) were seeded with a density of 0.45 x 106 cells/ml into a well of a 6-well 
plate. During the one hour incubation period the transfection mixture was prepared.  
Transfection mixture 1ml BacVector Insect Cell Medium 
5µl Gene Juice (Novagen) 
5µl BacMagic DNA (100ng total) 
5µl Transferplasmid (500ng total) 
 
All components were assembled in the order listed in a sterile tube and 
incubated at room temperature for 15-30min to allow complex formation. Immediately 
after medium was removed from the cells, 1ml transfection mixture was added 
dropwise to the center of the well. The plate was then incubated at 27°C in a moist bag. 
After 24h 1ml of BacVector Insect cell medium was added.  
After 5 days of incubation the supernatant was collected, centrifuged (10min, 
4,100 x g, 4°C) and transferred into a sterile tube. 10% FCS were added and the 
recombinant virus stock was stored in the dark at 4°C. 
2.2.3 Amplification of recombinant baculovirus 
Amplification of the recombinant viruses is necessary to generate high titer viral 
stocks for subsequent experiments. Sf9 cells were grown to a density of 
2 x 106 cells/ml and infected with a low moi (multiplicity of infection) of about 0.01-0.02. 
The flasks were incubated with shaking (27°C, 140rpm) until cells were well infected 
(4-5 days). The cells were harvested by centrifugation (10min, 2,000 x g, 4°C) and 10% 
FCS were added to the supernatant. The recombinant virus stock was stored in the 
dark at 4°C. The stocks were labeled as followed: 
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Initial virus stock 
 
Intermediate stock (IS) 
Working stock (WS) 
Recombinant baculovirus stock generated 
by co-transfection of Sf9 cells 
Low moi amplification of initial virus stock 
Low moi amplification of IS 
2.2.4 Virus PCR 
By isolating the virus-DNA of a working stock and subsequent amplifying a 
specific part of this DNA by PCR, it was possible to determine whether the virus stock 
contained amplified viruses at all and also to estimate the amount of these viruses. 
With this method it was possible to get a first information about the success of the virus 
amplification but whether the amplified viruses are infectious or not had to be 
determined by plaque assays (2.2.5). 
For Virus DNA isolation the GFX PCR DNA and Gel Purification Kit from GE 
Healthcare was used according to the protocol of the manufacturer. Briefly, 100µl virus 
solution were incubated with 600µl capture buffer for 15min at 60°C in a Thermomixer 
(1400rpm). The mixture was applied on a GFX column, incubated for 1min at room 
temperature and centrifuged (1min, 15,700 x g, room temperature). The column was 
washed with 300µl washing buffer and DNA was eluted with 50µl EB buffer (pre-
warmed to 72°C). 
For PCR, 5µl DNA were mixed with 20µl PCR-mastermix containing 1mM 
dNTPs, PCR buffer (QIAGEN), 0.5U Taq-polymerase (QIAGEN) and 5pmol of each 
primer of the appropriate Specific primer pairs for the amplification of full length α1, β3 
and γ2 encoding viruses listed below. 
α1:  forward α1-33XhoI, reverse α1+252 
β3 and β3His: forward β3-24-XbaI, reverse β3+242-XhoI 
γ2 and γ2His: forward γ2-38XhoI, reverse γ2+188-R 






5µl of the PCR product were analyzed by agarose gel electrophoresis (2.1.4). 
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2.2.5 Virus plaque assay 
Virus titers were determined by virus plaque assay and expressed as plaque 
forming units per ml (pfu/ml). 
Sf9 cells from a shaking culture were diluted to 0.45 x 106 to 0.5 x 106 cells/ml 
and 2ml of this dilution seeded in each well of a 6-well plate. The plate was incubated 
for at least 1 hour at 27°C. In the meantime 10-fold dilutions of the virus stock were 
prepared by mixing 70µl viruses with 630µl InsectXpress-medium in sterile tubes 
(10-1-10-7). After the cells had attached to the plate the medium was aspired and cells 
from each well were incubated with 500µl of the virus (10-2-10-7). 
After the viruses have been allowed to infect the cells, the supernatant was 
aspired and the cells were covered with 2ml of an agarose-overlay. For this 
agarose-overlay 3 vol. 1.3x Sf-900 medium (Novagen, pre-warmed to 37°C) were 
mixed with 1 vol. melted 4% agarosegel (Novagen) in a 100ml flask and incubated for a 
minimum of 30min at 37°C. 
After the agarose overlay has solidified (20min at room temperature) the plates 
were incubated in a zip lock bag containing a moistened towel for 6-7 days at 27°C. 
To visualize the plaques, 1ml MTT solution (1mg/ml Insect Xpress medium) was 
dropped on the cells and incubated for 45min in the dark in the incubator. After that 
time the yellow MTT stain not accumulated by the living cells was removed. The plates 
were incubated for 1 hour at 27°C and afterwards for 16 hours in the dark at room 
temperature. 
Clear plaques indicating cells that died due to an infection starting from a single 
virus, can be distinguished from the dark background of the living cells (see Fig. 11). 
Materials and methods  Katharina Grote 
 33 
 
Fig. 11: Picture of a virus plaque assay. In this 6-well plate Sf9 cells were infected with decreasing 












). The cells were stained 
with MTT after 6 days post infection. Colourless plaques were expressed as plaque forming units per ml 
(pfu/ml). 
2.2.6 Recombinant baculoviruses encoding for GABAA 
receptor subunits α1, β3 and γ2 
Recombinant baculoviruses encoding for a single GABAA receptor subunit were 
generated by Leila Wabnegger as described in her thesis ―High yield expression and 
His-tag purification of recombinant GABAA receptors using the Sf9-baculovirus 
Expression Vector System‖, 2005. 
The DNA fragments encoding the full-length α1 and β3 subunit were cloned into 
the pVL1393 transfer vector, those encoding the full-length γ2 subunit into the pVL1392 
transfer vector (Fig. 12). 
All the subunit encoding fragments were cloned behind the strong virus 
promoter polyhedron, which is a very late phase promoter. Transfection of Sf9 cells 
with linearized virus-genome DNA and the generated virus transfer plasmid led to 
homologous recombination, resulting in recombinant viruses encoding for the GABAA 
receptor subunits (Fig. 12) (Wabnegger 2005). 
As a means for purification of GABAA receptors it was decided to clone the 
His-tag on the N-terminal side of the β3 and γ2 subunit. The larger N-terminal 
extracellular domains are necessary for the formation of extracellular binding pockets. 
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In front of the eight histidine residues the first four amino acids of the mature protein 
were added. This was done because it is not clear whether the signal protease which 
cleaves the signal peptide also needs those first amino acids for recognizing its 
restriction site. To allow for a subsequent removal of the His-tag, a factor Xa-cleavage 
site (Ile-Glu-Gly-Arg) was added behind the histidine residues, separated by two amino 
acid residues (Gly-Thr) forming a KpnI-restriction site. The whole tag was generated by 
PCR and then cloned into a subunit encoding vector (Fig. 13) (Wabnegger 2005) 
 
Fig. 12: Schematic drawing of recombinant baculovirus transfer vectors containing either α1, β3 or 
γ2 encoding sequences. The subunit encoding sequences are cloned into the following baculovirus 
transfer vectors: α1 and β3: pVL1393, γ2: pVL1392. (TM: transmembrane domain, aa: amino acid). The 
arrow indicates where the signal protease cleaves the signal peptide away, resulting in the mature protein 
starting with amino acid one. The little tails indicate the glycosylation sites of the appropriate subunits 
(Wabnegger 2005). 
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Fig. 13: Schematic drawing of recombinant baculovirus transfer vector (pBacPAK8) containing 
either the His-tagged β3 or γ2 encoding sequences. The His-tags are situated between the signal 
peptide and the first amino acid of the mature proteins. In the schematically drawn His-tag, amino acids 
are represented by single letter code (Wabnegger 2005). 
2.3 Radioligand Binding Studies 
Radioligand binding studies were performed to determine the binding site 
density (Bmax) of receptors (either from membrane preparations or 
immunoprecipitations for antibody characterization) as well as the affinity (1/Kd) of a 
radioactively labeled ligand for a receptor. In these experiments, a saturated 
concentration of the radioactively labeled ligand was incubated with the receptor of 
interest, until steady state binding conditions were reached, producing increasing 
concentrations of ligand-receptor complex. The ligand-receptor complex is classically 
referred to as ―Bound‖, meaning the amount of ligand bound to the receptor. The 
unbound ligand is referred to as ―Free‖, meaning the amount of ligand that is free and 
able to interact with the receptor (Fig. 14). 
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Fig. 14: Schematic representation of the basic principles of receptor binding studies 
(www.tocris.com). 
Unfortunately, radioactive ligands usually bind not only to the site that is being 
studied and is therefore referred as the specific binding, but also to non-specific binding 
sites. Non-specific binding sites may be constituents of the tissue or sites on glass fiber 
filters and usually are sites exhibiting low affinity for the ligand. In order to distinguish 
specific binding from non-specific binding sites, a second set of incubations was run 
simultaneously using the radioactive ligand and an unlabeled ligand at a concentration 
(100-1000 x Kd) sufficient to block the binding of the radioactive ligand to the specific, 
but not to the unspecific sites. The amount of binding in the absence of unlabeled 
ligand is referred to as total binding. Binding in the presence of unlabeled ligand is 
referred to as unspecific binding or blank. The difference between these two is the 
specific binding. 
The equations for analysis of a saturation experiment are based on the 
assumption that the free concentration of the radioligand does not change, therefore 
less than 10% of the radioligand should be bound to the tissue. The equation for the 
resulting hyperbola is: 
 
Fig. 15: Equation to calculate bound ligand to the receptor (www.tocris.com). 
Kd is the concentration where 50% of the receptors are occupied by radioactive 
ligand. Kd is also a measure of the affinity of a ligand (drug) for a receptor, and is equal 
to k2/k1, where k1 is the association rate and k2 is the dissociation rate constant. As the 
concentration of radioligand increases, a point is reached where the amount of ligand 
bound no longer increases. This is the Bmax value and is a measure of the density [pM] 
or the amount [fmol/mg total protein] of the receptor in that tissue preparation (Fig. 16). 
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Fig. 16: Illustration of a saturation blot (www.tocris.com). 
Data was analyzed using the computer program Graph Pad Prism® from Graph 
Pad Software, Inc. Unspecific binding was determined at every second concentration of 
radioactive ligand used and then interpolated by linear regression. Specific receptor 
binding data were then further analyzed by non-linear regression. 
2.3.1 Preparation of Sf9 membranes for radioligand 
binding studies or SDS-PAGE 
Pellets from 10ml Sf9 cells were homogenized in 10ml 50mM Tris/Citrate buffer 
(TC50), with an Ultraturrax. This suspension was centrifuged for 20min at 150,000 x g, 
4°C. The supernatant was discarded and the membrane pellet homogenized in 5ml 
TC50 with the Ultraturrax. 
Aliquots for subsequent radioligand binding studies (2.3) were used 
immediately, the protein concentration was measured by BCA protein assay (Pierce) 
and the aliquots for SDS-PAGE (2.6) were centrifuged 30min at 13,000 x g 4°C and the 
pellets stored at -20°C. 
2.3.2 [3H]Muscimol binding assay 
Tritium [3H] labeled Muscimol is a compound that binds in the already published 
GABA pocket of GABAA receptors (Sieghart 1995; Johnston 1996; Barnard et al. 
1998). This pocket is between an alpha and a beta subunit in the extracellular domain 
of the receptor. With this ligand alpha and beta-containing GABAA receptors can be 
determined. 
For this binding assay Sf9 cell membranes (see 2.3.1) were used. 300-500µl 
cell membrane suspension were incubated with 40nM [3H]muscimol, in the absence or 
presence of 1mM GABA in a final volume of 1ml. To reach the steady state the 
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suspensions were incubated in the dark for 60min at 4°C. Immediately afterwards the 
suspensions were rapidly filtered with vacuum through Whatman GF/B filters. This step 
is important to separate ligand-receptor complexes from free ligands. The filters were 
washed twice with 3.5ml 50mM Tris/citrate buffer, pH 7.1, transferred into counting 
vials and subjected to liquid scintillation counting (Filter-CountTM, Packard). 
2.3.3 [3H]Flunitrazepam binding assay 
Tritium [3H] labeled Flunitrazepam is a compound, belonging to the class of 
benzodiazepines, that binds in the already published benzodiazepine pocket of GABAA 
receptors (Sieghart 1995; Johnston 1996; Barnard et al. 1998). This pocket is between 
an alpha and a gamma subunit in the extracellular domain of the receptor. With this 
ligand alpha and gamma-containing GABAA receptors can be determined. 
For this binding assay Sf9 cell membranes were used (2.3.1). 100µl cell 
membrane suspension were incubated with 10nM [3H]flunitrazepam, in the absence or 
presence of 100µM diazepam in a final volume of 0.5ml. To reach the steady state the 
suspensions were incubated in the dark for 90min at 4°C. For the following protocol 
see 2.3.2. 
2.3.4 Radioligand binding assay with solubilized 
receptors 
To perform a radioligand binding assay with Triton X-100 solubilized proteins, 
these proteins have to be precipitated before filtration. Therefore a polyethyleneglycol 
(PEG) precipitation assay was done. 
For a [3H]flunitrazepam PEG assay 100µl sample were incubated with 50mM 
Tris/citrate buffer pH 7.1, 150mM NaCl, 50µg serum-albumine, 15% PEG and 10nM 
[3H]flunitrazepam in the presence and absence of 100µM diazepam and incubated for 
90min at 4°C in the dark. The mixture was rapidly filtered with vacuum through 
Whatman GF/B filters, the filter washed three times with 3.5ml 8% PEG in TC50, 
transferred into counting vials and subjected to liquid scintillation counting (Filter-
CountTM, Packard). 
For a [3H]muscimol PEG assay 100µl sample were incubated with 50mM 
Tris/citrate buffer pH 7.1, 150mM NaCl, 50µg serum-albumine, 15% PEG and 40nM 
[3H]muscimol in the presence and absence of 1mM GABA and incubated for 60min at 
4°C in the dark. The mixture was rapidly filtered with vacuum through Whatman GF/B 
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filters, the filter washed twice with 3.5ml 8% PEG in TC50, transferred into counting 
vials and subjected to liquid scintillation counting (Filter-CountTM, Packard). 
2.4 Purification of His-tagged receptors 
2.4.1 Preparation of Sf9 cell membranes 
Pellets of 200ml Sf9 cells were homogenized in 15ml homogenization buffer 
with an Ultraturrax and ultracentrifuged (150,000 x g, 20min, 4°C). The supernatant 
was discarded and the pellet was resuspended in 15ml washing buffer causing an 
osmotic disruption of vesicular structures. 
Homogenization buffer 10mM Na-Phosphate 
300mM Sucrose 
pH 7.5 
1 Complete Protease Inhibitor Cocktail 
Tablet per 50ml, 4°C 
Washing buffer 10mM Na-Phosphate 
pH 7.5 
1 Complete Protease Inhibitor Cocktail 
Tablet per 50ml, 4°C 
 
After centrifugation (48,000 x g, 4°C, 60min), the resulting pellet was 
resuspended in the same volume washing buffer. 
An aliquot was taken for the determination of the protein concentration by BCA 
protein assay (Pierce). The suspension was again centrifuged for 60min at 48,000 x g, 
4°C. The dry pellet was stored at -80°C. 
2.4.2 Preparation of Sf9 cell membrane extracts 
Frozen Sf9 cell membranes were thawed on ice and resuspended in extraction 
buffer (40ml/200ml Sf9 membrane pellet). 
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Extraction buffer 0.5% Triton X-100 
1M NaCl 
50mM NaH2PO4 pH 7.5 
10-20mM Imidazole 
1 Complete Protease Inhibitor Cocktail 
Tablet without EDTA per 50ml, 4°C 
 
After addition of DNaseI (Sigma, 5mg/40ml extraction buffer), the suspension 
was incubated under stirring for 2 hours at 4°C and centrifuged (150,000 x g, 60min, 
4°C). The clear supernatant was then used for Ni-NTA affinity chromatography. 
2.4.3 Purification of GABAA receptors via a Ni-NTA 
column 
2.4.3.1 Ni-NTA spin columns 
In order to optimize the stringency of the washing conditions, small amounts of 
His-tagged receptors were purified by using Nickel-Nitrilotriacidic acid (Ni-NTA) spin 
columns (QIAGEN). The column was equilibrated with 600µl of the extraction buffer 
(2.4.2) and centrifuged for 2min at 700 x g at 4°C. Then the extract (1-3ml) was applied 
onto the column with a maximum of 600µl per centrifugation step and centrifuged for at 
least 5min at 270 x g at 4°C. The flow-through was collected. The column was washed 
with buffers containing increasing concentrations of imidazole (40mM, 80mM) and the 
proteins eluted twice with 200µl elution buffer. Flow-through, wash fractions and 
eluates were analyzed by SDS-PAGE and Western blot (2.6). 
40mM imidazole buffer 40mM Imidazole pH 7.5 
0.5% Triton X-100 
300mM NaCl 
50mM Sodiumphosphate pH 7.5 
Elution buffer 250mM Imidazole pH 7.5 
0.5% Triton X-100 
300mM NaCl 
50mM Sodiumphosphate pH 7.5 
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2.4.3.2 Ni-NTA column purification 
Larger amounts of His-tagged GABAA receptors were purified on Ni-NTA-
agarose beads (QIAGEN) packed into empty columns (Filtration Column, Separtis). 
The column was packed at room temperature, washed with MilliQ water and 
transferred to the cold room. There the column was equilibrated with 2 bed volumes of 
extraction buffer (see 2.4.2). The extract was applied onto the column (6-10ml/h) and 
the flow-through was collected. The column was washed 2 times with 3 bed volumes 
extraction buffer, followed by 3 bed volumes of buffer with optimized imidazole 
concentration (see 2.4.3.1). The His-tagged GABAA receptors were eluted 6 times with 
1 bed volume of elution buffer containing 250mM imidazole. The eluates were collected 
separately and stored at 4°C for further analysis. 
2.5 Benzodiazepine column-affinity-
chromatography 
Frozen Sf9 cell membrane preparations (see 2.4.1) were thawed and 
resuspended in extraction buffer. The suspension was stirred for two hours at 4°C and 
centrifuged (145,000 x g, 4°C, 60min). The clear supernatant (extract) was then used 
for affinity chromatography. 








Prior to use benzodiazepine column (Fuchs and Sieghart 1989) was washed 
with a buffer containing 10mM HEPES pH 7.4 and 0.2% Triton X-100. Then the column 
was equilibrated for about 6 hours with the extraction buffer. The extract was applied to 
the column at a rate of 7-8ml/h. The column was washed with the extraction buffer for 
one day with a rate of ~5ml/h, followed by 20ml of elution buffer. 
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Elution buffer 10mM HEPES 
150mM KCl 






Proteins bound to the column were eluted at a rate of 5ml/h with a freshly 
prepared elution buffer, containing the benzodiazepine tranxilium 
(Dipotassiumclorazepat). Therefore 4mg/ml tranxilium were dissolved in the elution 
buffer and the pH was adjusted to 7.6 with HEPES powder. The eluted proteins were 
collected in 10ml aliquots and used for subsequent experiments. 
The column was washed with elution buffer without tranxilium and afterwards 
over night with a buffer containing 10mM HEPES and 0.2% TritonX-100, pH 7.7, 
followed by washing over 3-4 days with the same buffer adjusted to pH 7.4. Finally, the 
column was washed with 100ml of a 6M urea-solution, followed by a last washing step 
with 10mM HEPES and 0.2% TritonX-100 and stored at 4°C. 
2.6 SDS-PAGE, Western blot analysis & 
Coomassie blue staining 
2.6.1 SDS-PAGE 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed according to Invitrogen’s NuPAGE manual. In a discontinuous system, 
proteins were separated on 10% SDS-polyacrylamide gels, consisting of a 5% stacking 
and a subjacent 10% separating gel. 
Immediately after the separating gel was prepared, it was overlaid 2-3mm with 
0.1% SDS. After 4h of polymerization at room temperature the gels could be stored at 
4°C. Before using them, the gel surface was washed with 1x stacking gel buffer and 
overlaid with the stacking gel. Immediately, a comb was stacked into the gel avoiding 
air bubbles. 
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Separating gel 10% of a 30% Acrylamide/Bis solution-
29:1-(3.3% C) (BioRad) 
0.1% SDS 
25% 4x Separating gel buffer (1.5M Bis-
Tris, pH 6.4) 
0.1% Ammoniumpersulfate (APS) 
0.001% Tetramethyl-ethylenediamine 
(TEMED) 
Stacking gel 5% of a 30% Acrylamide/Bis solution 
29:1-(3.3% C) (BioRad) 
0.1% SDS 
25% 4x Stacking gel buffer (0.5M Bis-




After polymerization the comb was removed carefully and the slots washed with 
1x NuPAGE MOPS SDS running buffer. 






After the gel boxes were assembled and the gels were mounted, the outer 
chamber was filled with 600ml 1x NuPAGE MOPS SDS running buffer and the inner 
chamber was filled with 200ml of the same running buffer containing 500µl NuPAGE 
antioxidant. 
Prepared membrane samples can be used directly for SDS-PAGE. Extracted 
proteins have to be precipitated before applying on a gel. This precipitation was 
performed with a chloroform/methanol precipitation. Therefore the sample was 
vortexed with 1 volume of methanol and ½ volume of chloroform and centrifuged for 
5min at 18,000 x g, 4°C. After the centrifugation the proteins stay in the interphase. The 
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upper phase was removed and 2 volumes of methanol added, vortexed and again 
centrifuged for 30min at 18,000 x g, 4°C. The supernatant was removed and the pellet 
dried completely. This pellet can then be used immediately or stored at -20°C, like a 
membrane protein pellet, for further analysis. 
The samples of interest were mixed with 1x NuPAGE LDS sample buffer and 1x 
NuPAGE reducing agent, denatured while shaking for 10min at 70°C in a 
Thermomixer, and centrifuged at 17,900 x g for 2min at room temperature. 10-20µl 
(1µg/µl) were loaded carefully into each slot of the stacking gel. MagicMarkTM XP 
Western Standards (Invitrogen) was loaded as marker for the protein size into one slot. 
The proteins were separated with 200V (max. 125mA/gel) for 45min. When the gel run 
was finished, the gels could be used for Western blot analysis (2.6.2) or Coomassie 
blue staining (2.6.3). 
2.6.2 Western blot 
In the meantime PVDF membranes (polyvinylidene fluoride, Millipore 
Immobilon-P Transfer membrane) in the size of 6 x 8cm were moistened for 20sec in 
methanol, shortly washed in MilliQ ultra pure water, and stored in 1x transfer buffer 
containing 10% methanol until use for blotting. 




The above mentioned gels and two Whatman filter papers (6 x 8cm) per gel 
were also moistened in 1x transfer buffer. The blot was assembled bubble free. The 
plus pole was in contact with a Whatman filter. On top of the filter there was the PVDF 
membrane, then the gel, again a Whatman filter and the minus pole. The proteins were 
transferred onto the membrane in 1x transfer buffer with 58mA/gel (max. 20V) for 1h. 
Thereafter the blot was disassembled and the membranes were shaken in blocking 
buffer for 1h at room temperature. 
Blocking buffer 1.5% Dry milk powder 
0.1% Tween 20 
1x PBS 
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After this the remaining binding sites on the membrane should have been 
blocked. The blots were transferred into new boxes which contained the primary 
antibody of interest in a concentration of 1µg/µl (diluted in blocking buffer). They were 
kept overnight at 4°C shaking. 
On the next day the blots were washed three times with blocking buffer for 
20min and incubated with the secondary antibody (alkaline phosphatase conjugated 
AffiniPure F(ab’)2 Fragment goat anti-rabbit IgG (H+L), Jackson Immuno Research 
Laboratories) diluted 1:2,000 in blocking buffer for 1h at room temperature. To remove 
the secondary antibody another three washing steps in blocking buffer for 20min each 
were performed. After that another two final washing steps with assay buffer were done 
(5min and 10min). 




Finally the blots were overlaid with the substrate CDP-Star (Applied 
Biosystems, Bedford, MA) and diluted 1:1,000 in assay buffer. After the blots were 
exposed in the Fluor-S Multi-Imager (Bio-Rad Laboratories, Hercules, CA), the reaction 
of alkaline phosphatase with CDP-Star could be visualized and the emerging 
chemiluminescent signals could be quantified by densitometry. The signal intensity was 
evaluated with Quantity One®. 
To establish the linear range of the detection system, antibody generated 
signals were measured at a range of protein and antibody concentrations. 
Immunoreactivities were within the linear range under the used experimental 
conditions, thus permitting a direct comparison of the amount of antigen between each 
sample of a lane. After evaluation, the blots were stored in assay buffer at 4°C. 
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2.6.3 Coomassie blue staining 
After an SDS-PAGE (2.6.1) the proteins can be stained unspecifically in the 
polyacrylamidgel. Therefore the gel was washed three times with MilliQ water. About 
20ml staining solution (Simply Blue™ Safestain, Invitrogen) per gel were used and 
incubated for 1 hour. Then the staining solution was discarded and the gel washed with 
MilliQ water for several hours or over night, until the background is clear or light blue. 
The gel with the stained protein bands can be scanned for further quantitative 
measurements. 
2.7 Generation and purification of polyclonal 
antibodies 
For all methods to be used antibodies were needed, which specifically detect 
different subunits of the GABAA receptor. Some of these antibodies were directed 
against small peptides, others against fusion proteins representing sequences that are 
unique for the respective subunit. Immunizations with antigens were done in rabbits. 
2.7.1 Peptide antibodies 
The peptide for the subunit α1(1-9) was custom synthesized containing an 
additional N- or C-terminal cysteine (piCHEM, Graz, Austria), which was coupled to 
either keyhole limpet hemocyanin or to Thiopropyl Sepharose 6B (Amersham 
Pharmacia Biotech). The keyhole limpet hemocyanin (KLH) enhances immunogenicity 
in immunized rabbits. The coupling to the Thiopropyl Sepharose 6B is necessary to 
obtain purified antibodies. 
2.7.2 Fusion protein antibodies 
The GABAA receptor subunit sequences of interest were α1(328-382), β3(1-13), 
β3(345-408), γ2(1-33) and γ2(319-366). These sequences had already been cloned 
into the pMALc vector (New England Biolabs, Beverly, MA) and by that were fused with 
the maltose binding protein (MBP), an enhancer of immunogenicity and were 
additionally tagged with seven histidines to enable purification with Ni-NTA agarose 
(Qiagen). The fusion proteins resulting from expression of the vector product in 
bacteria were used for immunization of rabbits. The same sequences had also been 
cloned into a modified vector pGEX-4T3 (Amersham Pharmacia Biotech), which in 
addition to gluthathione S-transferase (GST) encodes for seven C-terminal histidines. 
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Fusion proteins obtained by expression of this vector were coupled to Affigel 10 
(BioRad) and were used for purification of antisera and separation from antibodies 
directed against MBP. 
2.7.3 Expression of fusion proteins 
The above mentioned vectors encoding for fusion proteins were transformed 
into E.coli XL1 blue (Stratagene, La Jolla, CA). For expression E.coli bacteria were 
cultured overnight (Thermomixer 180-200rpm at 37°C) in 20ml LB-rich medium, 
containing 50µg/ml ampicillin. 4ml of the overnight culture were transferred into 250ml 
of fresh pre-warmed (37°C) LB-rich medium containing 50µg/ml ampicillin and grown 
(Thermomixer 250rpm at 37°C) to an OD600 of 0.5-0.7. The expression of the fusion 
protein was induced with isopropyl-β-D-1-thiogalactopyranoside (IPTG, end 
concentration should be 1mM) and the bacteria were again incubated and grown to an 
OD600 of 1.6. The cells were incubated for 10min on ice and harvested by centrifugation 
(15,000g 15min 4°C). The pellets were kept at room temperature for 30min and stored 
overnight at -20°C. After thawing, the pellets were extracted in 1ml per 50ml culture 
with 6M guanidine-HCl in 1x QE during intensive stirring for 1h at room temperature. 




The suspension was then centrifuged (43,000 x g 30min at 20°C) and the 
supernatant was applied to a Ni-NTA agarose column. The column was washed five 
times with 2.5ml 8M urea in 1x QE at pH 6.3. The fusion protein was eluted by washing 
five times with 0.5ml 8M urea in 1x QE at pH 5.9 and six times with 1ml 8M urea in 1x 
QE at pH 4.5. Finally the purity of the eluates was controlled on a 10% polyacrylamide 
gel (2.6.1) and the eluates were stored at 4°C. 
For immunization, MBP fusion proteins were diluted in 1x PBS. GST fusion 
proteins, used for coupling to Affigel 10, were brought to pH 7.0 - 7.5. 
2.7.4 Immunization of rabbits 
In order to obtain specific antibodies directed against defined subunits of the 
GABAA receptor, several rabbits were immunized either with MBP fusion proteins or 
KLH coupled peptides. For this, 100µg of the fusion protein or KLH coupled peptides 
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were used and diluted in 1x PBS to a total volume of 750µl. In practice 1.5ml of this 
solution, sufficient for two animals, were emulsified with 2ml of complete Freund’s 
adjuvant (for the first immunization), containing 1mg/ml inactivated and dried 
mycobacterium tuberculosis (Sigma) that functions as a booster for the immune 
reaction, or with 2ml of incomplete Freund’s adjuvant (for all following immunizations) 
and injected into the rabbits. 
Every three to five weeks the immunization was repeated until the titer or the 
specificity of the antibodies decreased. Ten to fourteen days after each immunization 
cycle the rabbits were bled and then every week until the next immunization. The 
antibodies were characterized by Western blot, immunoprecipitation, and/or 
immunohistochemistry analysis. 
2.7.5 Purification of antibodies 
To obtain clear blood serum the blood cells and platelets were pelleted by 
centrifugation (4,600 x g 2h at 4°C). The supernatant was stored overnight at 4°C and 
centrifuged (48,000 x g 30min at 20°C) again the next day. In the meantime the 
required GST columns were brought to room temperature and washed with 20ml 1x 
PBS. After centrifugation, the supernatant was diluted with 1/9 volume of 10x PBS, 
applied to an appropriate immunoaffinity column, and chromatographed. The efflux was 
collected and stored at 4°C for a possible second chromatography. To remove 
unbound protein, the column was washed with 50ml 1x PBS. The bound antibodies 
were eluted in ten to fifteen 1ml fractions with alkaline elution buffer. 




Each fraction was directly eluted into 100µl of acidic neutralization buffer and 
mixed rapidly to immediately neutralize the pH. 
Acidic neutralization buffer 1M NaH2PO4 
pH 4.4 
 
The protein concentrations of the purified antibodies were measured with a 
bicinchoninic acid (BCA) protein assay kit (Pierce) according to manufacturer’s 
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instruction. After freezing the antibodies with liquid nitrogen they were stored at -20°C. 
The used column was washed several times: 20ml elution buffer, 20ml 1x PBS, 20ml 
elution buffer with the opposite pH that was used for the elution and again with 30-50ml 
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3 RESULTS 
This thesis is based on the results of the thesis from Leila Wabenegger, in 
which the possibility of expressing α1β3γ2-containing recombinant GABAA receptors in 
Sf9 cells was evaluated. With the present experiments we wanted to establish large 
scale production of pure, non degraded α1β3γ2 GABAA receptors for further structural 
analysis, such as crystallization, photoaffinity labeling and surface plasmon resonance 
investigations. 
3.1 α1β3His8γ2 GABAA receptors 
In the first experiments already cloned and tested single viruses for the α1, β3 or 
γ2 subunits were used. A His-tag had been cloned into the β3 subunit by Leila 
Wabenegger for an additional option to purify the receptor with a Ni-NTA column. 
3.1.1 Determination of the optimal conditions for the 
expression of α1β3His8γ2 GABAA receptors 
Previous experiments had shown that the ratio of the three viruses used for 
co-infection had to be in a certain range for the production of correctly assembled 
receptors. To establish this range Sf9 cells were co-infected with different combinations 
of viruses, harvested three days post infection (dpi) and subjected to [3H]flunitrazepam 
binding assays. Then specific binding was calculated (Tab. 3). 
In addition, different multiplicities of infection (moi) were used. The multiplicity of 
infection defines the ratio between viruses and Sf9 cells. For instance, a moi of 1 
means that, each Sf9 cell on average was infected with a single virus particle, in the 
case of a moi of 3 each cell was infected with three virus particles, etc. This factor 
could also influence the receptor expression level, because huge amounts of viruses 
could lead to degraded receptors or to premature cell death. 
Another parameter in recombinant protein expression with Sf9 insect cells was 
time. It was necessary to find out the optimal time point for harvesting the cells after 
expression of the recombinant receptor, when the expression level was high but 
unspecific degradation of the expressed recombinant protein was still low. Normally the 
protein expression was stopped after 72 hours (3 days) (Fig. 17). 




















6: pos. control AB
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Fig. 17: Western blot experiment of different harvesting time points of an α1β3His8γ2 expression in 
Sf9 cells. Sf9 cells were co-infected with α1, β3His8 and γ2 subunits and harvested after 1.0, 1.5, 2.0, 2.5 
and 3.0 days post infection (dpi). Membranes were prepared and the same amount of total protein was 
subjected to an SDS-PAGE and Western blot analysis with subunit specific α1L, β3N and γ2L antibodies 
performed. 
The α1 subunit was already expressed after 24h (1.0 dpi, lane 1) at the apparent 
molecular mass of 50kDa compared to the positive control of the antibody in lane 6. 
After 1.5, 2.0, 2.5 and 3.0 days post infection the expression level seemed to be high 
and the amount of expressed protein stable. Additionally, degraded α1 bands were 
stained at about 45kDa in lane 2-5, which were overlapping with the α1 band. The other 
protein bands at 20 and 30kDa were cross-reactivities of the antibody. 
The β3 subunit was not stained after 24h (lane 1). This subunit was expressed 
quite well from 1.5-3.0 days post infection (lane 2-5) and stained at the apparent 
molecular mass of 55kDa, compared to lane 6, the positive control of the antibody. Due 
to the His-tag, the expressed β3His 8 subunit runs at a higher molecular mass in the 
SDS-PAGE compared to the positive control. Again a degradation product of the 
subunit was slightly stained in lane 2-5 at the apparent molecular mass of 45kDa. The 
stained bands at 35kDa were cross-reactivities of the used antibody. 
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The γ2 subunit could be stained and therefore was expressed from 24h on in all 
samples at the apparent molecular mass of 48kDa. The correct molecular mass of the 
γ2 subunit could be compared to the positive control of the antibody in lane 6. Similar to 
the other two subunits, the γ2 subunit showed degradation at about 45kDa. The γ2 
antibody unspecifically stained protein bands from 15-40kDa. The cross-reactivity-
bands of the alpha1L, beta3N and gamma2L specific antibodies used in this thesis 
were already checked and determined before. Bands at higher molecular masses 
indicated aggregates of the subunits, which were not dissolved properly during 
SDS-PAGE. 
This experiment indicated that the α1, the β3 and the γ2 subunit were expressed 
at a high level after 36h (1.5dpi). The intensity of the specific bands between 1.5 and 
3.0 days post infection seemed to be the same, meaning that the expression of the 
protein could not be enhanced by more time. 
The degradation could not be diminished by harvesting the cells at an early time 
point (24h). The GABAA receptor subunits were expressed under a late promoter in the 
Sf9 cells and therefore needed a certain time span to be expressed and the receptor to 
be assembled. To confirm these Western blot results, a [3H]flunitrazepam binding 
assay was performed (Tab. 2). 
dpi pmol [
3













H]flunitrazepam binding assay experiment at various harvesting time points of Sf9 cells, 
expressing α1β3His8γ2 GABAA receptors. Sf9 cells were co-infected with α1, β3His8 and γ2 subunits and 
harvested at different days post infection (dpi). Membranes were prepared, receptors were incubated with 
10nM [
3
H]flunitrazepam ± 100µM diazepam and specific binding (pmol [
3
H]flunitrazepam/mg total protein) 
was calculated. 
The binding assay provided similar results as the Western blot (Fig. 17). At a 
harvesting time point of 24h after infection (1.0 dpi), the expression level was very low. 
After 36h (1.5 dpi) the expression reached 1.0 picomol receptor per mg total protein 
and remained constant with a small increase to 1.2pmol at 2.5 dpi. 
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To reach a high expression level and to keep the degradation of the proteins 
low, we decided to harvest the Sf9 cells between 2-3 days post infection, but this had 
to be tested for different constructs or ratios of subunits. 
Knowing the appropriate harvesting time point of the Sf9 cells, the next 
expression experiments were performed to investigate different ratios of subunits for a 
high receptor expression level (Tab. 3). Membranes from harvested Sf9 cells were 
prepared (2.3.1) and the amount of receptors in a sample was determined with 
radioligand binding assays with 10nM [3H]flunitrazepam (2.3.3), in the presence and 
absence of diazepam. The resulting counts per minute (cpm) were converted to pmol 
receptor binding sites per mg total protein (Tab. 3). 
Ratio α1 : β3His8 : γ2 moi pmol [
3













Tab. 3: Optimization of the protein expression of α1β3His8γ2 GABAA receptors in Sf9 cells. Sf9 cells 
were co-infected with different ratios of α1, β3His8 and γ2 subunits and different moi (multiplicity of 
infection). Cells were harvested after 3 days and membranes were prepared. Receptors were incubated 
with 10nM [
3
H]flunitrazepam ± 100µM diazepam and specific binding (pmol [
3
H]flunitrazepam/mg total 
protein) was calculated. 
The resulting pmol [3H]flunitrazepam/mg total protein indicated the amount of 
GABAA receptors containing α1, β3 and γ2 subunits. The used ratios (2:1:1 and 3:1:1) 
and moi (1 and 2) showed no significant difference in the receptor expression level. 
Under all conditions approximately 3pmol α1β3His8γ2 GABAA receptors were 
expressed. The variation of the expressed 3pmol and the expressed 1pmol shown in 
Tab. 2, lie in the same expression level range. 
We decided to use both ratios 2:1:1 and 3:1:1 with a moi = 1 and a harvesting 
time point of 72 hours (3 days). 
3.1.2 One-step purification with a Ni-NTA column 
Proteins, containing a Histidine (His)-tag consisting of a minimum of six His, can 
be purified over a Nickel-Nitrilotriacidic acid (Ni-NTA) column. Bound proteins can then 
be eluted from the column by competitive displacement with increasing amounts of 
imidazole. 
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For our experiments a pellet of 330ml harvested Sf9 cells, expressing 
α1β3His8γ2 GABAA receptors, was used. This pellet contained 240pmol 
[3H]flunitrazepam binding sites and 2200pmol [3H]muscimol binding sites. With the 
assumption, that 1pmol receptor is equal to 250ng receptor, 240pmol were equal to 
60µg receptor protein (Tab. 4). 
Membranes were prepared from the Sf9 pellet (2.4.1), extracted in 80ml 0.5% 
Triton X-100 extraction buffer (2.4.2) and the clear supernatant was applied to a 750µl 
Ni-NTA agarose column. The column was washed with 4ml of a 40mM imidazole buffer 
and then with 1ml aliquots of an 80mM, 100mM, 120mM and 150mM imidazole buffer. 
The proteins were eluted with 5 x 1ml 200mM imidazole buffer aliquots (eluates 1-5). 
The yield of the washing and elution steps was determined with PEG 
precipitation and 10nM [3H]flunitrazepam or [3H]muscimol radioligand binding assays. 
The purity of the receptor was tested with an SDS-PAGE with subsequent Coomassie 
blue staining (Fig. 18). The radioligand binding assay data are summarized in Tab. 4. 
The binding assay results indicated a disequilibrium of α1β3γ2 
([3H]flunitrazepam) to α1β3 ([
3H]muscimol) containing receptors in the isolated 
membranes. Only about 10% of the GABA receptors contained a γ subunit as indicated 
by the ratio of pmol [3H]flunitrazepam compared to pmol [3H]muscimol binding. 
The one-step purification also indicated a massive loss of receptors. The 
membrane extract contained 235pmol [3H]flunitrazepam binding sites or 60µg receptor 
protein; 186pmol of these receptors were retained by the column and after elution only 
77pmol or 20µg receptor protein remained. This indicated either a loss or a partial 
inactivation of 2/3 of the receptors. Thus only 1/3 of the receptors was purified in a way 
able to bind [3H]flunitrazepam and was then concentrated in 5ml. 







Membrane preparation 240 2200 
Extract 235 - 
Retention 186 - 
















Tab. 4: One-step purification of α1β3His8γ2 GABAA receptors with a Ni-NTA column. Sf9 cells were 
co-infected with α1, β3His8 and γ2 subunits and harvested after 3 days. Membranes and extracts were 
prepared and receptors purified via a Ni-NTA column. Samples from different stages of the purification 
were incubated with 10nM [
3
H]flunitrazepam ± 100µM diazepam or 40nM [
3
H]muscimol ± 1mM GABA and 
specific binding (pmol [
3
H]flunitrazepam or pmol [
3
H]muscimol) was calculated. 
 









Fig. 18: SDS-PAGE and Coomassie blue staining of the one-step purification of α1β3His8γ2 GABAA 
receptors with a Ni-NTA column. Sf9 cells were co-infected with α1, β3His8 and γ2 subunits and 
harvested after 3 days. Membranes and extracts were prepared and receptors purified via a Ni-NTA 
column. Aliquots from different washing (W1-W2: 40mM, W3: 80mM, W4: 120mM, W5-W6: 150mM 
imidazole) and elution steps (E1-E5: 200mM imidazole) were precipitated and subjected to SDS-PAGE 
and Coomassie blue staining. 
The Coomassie blue staining of the one-step purification of α1β3His8γ2 GABAA 
receptors in Fig. 18 showed an increasing staining of a protein band at the apparent 
molecular mass of 55kDa in the elution steps E1-E5, representing the β3His8 subunit. 
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The signal of the α1 subunit at about 50kDa in the eluates was partially covered by that 
of another protein of the same size in all samples. The γ2 subunit at the apparent 
molecular mass of 48kDa was not stained with Coomassie blue, indicating that purified 
receptors contained mainly α1 and β3His8 subunits. These subunits can form functional 
β3His8 homo-oligomeric and α1β3His8 hetero-oligomeric GABAA receptors. The correct 
molecular mass of the subunits was also confirmed by Western blot analysis, where α1, 
β3 and γ2 specific antibodies were used (not shown). All other stained bands on the 
Coomassie blue gel presented other, non GABAA receptor proteins from the Sf9 
extract, which also were retained by and eluted from the column. 
Both, the radioligand binding assay (Tab. 4) and the Coomassie blue staining 
results (Fig. 18) of the purification of α1β3His8γ2 GABAA receptors with a Ni-NTA 
column, showed that more β3His8 homo-oligomeric and α1β3His8 hetero-oligomeric 
receptors than α1β3His8γ2 GABAA receptors were expressed and purified via the 
His-tag with a Ni-NTA column. 
3.1.3 Two-step purification with a benzodiazepine-
affinity column and a subsequent Ni-NTA column 
To avoid enrichment of β3His8 and α1β3His8 receptors and to enhance the 
purification of α1β3His8γ2 receptors, a two-step purification with a benzodiazepine and a 
subsequent Ni-NTA column with more material was performed. Benzodiazepines bind 
to the α/γ interface, so only α1β3γ2 receptors were retained by this column. The 
receptors could be concentrated and further purified afterwards with the Ni-NTA 
column. 
3.1.3.1 Benzodiazepine-affinity column 
For the purification with a benzodiazepine column, a pellet of 6360ml harvested 
Sf9 cells, expressing α1β3His8γ2 GABAA receptors was used. This pellet contained 
2820pmol [3H]flunitrazepam binding sites corresponding to 700µg receptor protein. 
Membranes were prepared from the Sf9 pellet (2.4.1) and extracted in 580ml 0.5% 
Triton X-100 extraction buffer (2.4.2). The clear supernatant was applied to a 
benzodiazepine-affinity column (2.5). The yield of the washing and elution samples was 
determined by PEG precipitation and [3H]flunitrazepam radioligand binding assay 
(2.3.3). The radioligand binding assay data are summarized in Tab. 5. 
The benzodiazepine-affinity column retained 2085pmol [3H]flunitrazepam 
binding sites from 2380pmol of the binding sites in the extract (Tab. 5). After the elution 
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340pmol receptors or 85µg receptor protein remained. Thus, about 15% of the 
receptors ([3H]flunitrazepam) from the extract were purified. 
 pmol [
3
H]flunitrazepam Calculated µg receptor protein 
Membrane preparation 2820 700 
Extract 2380 595 





All eluates 340 85 
Tab. 5: Benzodiazepine-affinity column purification of α1β3His8γ2 GABAA receptors. Sf9 cells were 
co-infected with α1, β3His8 and γ2 subunits and harvested after 3 days. Membranes and extracts were 
prepared and receptors purified via a benzodiazepine-affinity column. Samples from different stages of the 
purification were incubated with 10nM [
3
H]flunitrazepam ± 100µM diazepam and specific binding (pmol 
[
3
H]flunitrazepam) was calculated. 
For further purification via a Ni-NTA column, the eluates were dialyzed with a 
0.2% Triton X-100 buffer over night (0.2% Triton X-100, 300mM NaCl, 25mM Na-
phosphate, 0.06% Asolectin, 1 Complete Protease Inhibitor Cocktail Tablet without 
EDTA per 50ml, 4°C). 
3.1.3.2 Ni-NTA column 
The 340pmol dialyzed α1β3His8γ2 GABAA receptors were applied to a Ni-NTA 
column (0). The column was washed with a 40mM and an 80mM imidazole buffer and 
the proteins were eluted with a 120mM imidazole buffer (eluates 1-3). 
The yield and the purity of the washing and elution steps were determined with 
PEG precipitation and 10nM [3H]flunitrazepam radioligand binding assay. In addition an 
SDS-PAGE with subsequent Coomassie blue staining was performed. The radioligand 
binding assay data are summarized in Tab. 6. 
From the Ni-NTA column about 80pmol or 25% of the applied receptor protein 
were eluted (Tab. 6). Thus, from 2820pmol receptor protein in Sf9 membranes, 
corresponding to 700µg receptor protein, 80pmol or 20µg receptor protein remained 
after the two-step purification. The remaining 20µg receptor protein represented 3% of 
the starting material and had a purity of estimated 90%. 











Tab. 6: Second step of the purification of α1β3His8γ2 GABAA receptors using a Ni-NTA column. 
Purified receptors from a benzodiazepine-affinity column were dialyzed and subjected to a Ni-NTA column. 
The applied sample to the Ni-NTA column and the eluates were incubated with 10nM [
3
H]flunitrazepam ± 
100µM diazepam and specific binding (pmol [
3
H]flunitrazepam) and receptor protein [µg] were calculated. 








Fig. 19: SDS-PAGE and Coomassie blue staining of the purification of α1β3His8γ2 GABAA receptors 
with a benzodiazepine-affinity and a Ni-NTA column. Sf9 cells were co-infected with α1, β3His8 and γ2 
subunits and harvested after 3 days. Membranes and extracts were prepared and receptors purified via a 
benzodiazepine-affinity column. Eluates were dialysed and loaded on a Ni-NTA column. Aliquots were 
precipitated, subjected to an SDS-PAGE and Coomassie blue staining. E BZ: Eluates of the 
benzodiazepine column, FT: Flow through Ni-NTA column and elution steps of the Ni-NTA column E1: 
40mM imidazole, E2: 80mM imidazole and E3: 120mM imidazole. 
The Coomassie blue staining (Fig. 19) showed highly purified α1β3His8γ2 
GABAA receptors. There was hardly any contamination in the Coomassie blue staining. 
The α1 subunit was stained at an apparent molecular mass of 50kDa, the β3 subunit at 
55kDa and the γ2 subunit at 48kDa. Compared to the one-step purification via a 
Ni-NTA column, the γ2 band was stained with Coomassie blue. The receptor was 
enriched comparing the benzodiazepine eluate (E BZ) to the subsequent Ni-NTA 
column eluates (E1-E3). The correct molecular mass of the subunits was confirmed 
with Western blot analysis, where α1L, β3N and γ2L specific antibodies were used (not 
shown). 
The purification of α1β3His8γ2 GABAA receptors by two columns showed an 
enormous loss of about 97% of the expressed protein but on the other hand an 
extremely pure and concentrated receptor at the end. 
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3.2 α1β3γ2His8 GABAA receptors 
Using the His-8 tag at the β3 subunit not only α1β3γ2 but also α1β3 hetero-
oligomeric and homo-oligomeric β3 receptors were formed. Using a two-step 
purification resulted in a highly purified α1β3His8γ2 receptor, but the loss of receptors in 
this procedure was huge. 
To avoid these problems, the His-tag was cloned into the γ2 subunit. When 
α1β3γ2His8 receptors are expressed in Sf9 cells, only this receptor type should be 
purified via a Ni-NTA column. Therefore, for the next experiments, viruses encoding the 
α1, β3 and the His8-tagged γ2 subunit were used. It was hoped that with a single 
purification step a purity of the α1β3γ2 receptors similar to that of the receptors purified 
with two columns could be reached. 
3.2.1 Determination of the optimal conditions for the 
expression of α1β3γ2His8 GABAA receptors 
Before starting large expression and purification experiments of α1β3γ2His8 
GABAA receptors via a Ni-NTA column, optimal expression conditions with a high 
expression level and little degradation had to be determined (Tab. 7). For that, different 
ratios of α1, β3 and γ2His8 viruses, different multiplicities of infection (moi) and different 
harvesting times (dpi) were tested. 
Sf9 cells were harvested after 2 and 3dpi. Membranes from harvested Sf9 cells 
were suspended in a Tris/Citrate buffer (2.3.1) and radioligand binding assays with 
10nM [3H]flunitrazepam or 40nM [3H]muscimol were performed (2.3.3, 2.3.2) (Tab. 7). 
In addition to the binding assay experiments, the samples were also tested for 
degradation of receptors with SDS-PAGE and Western blot experiments (2.6) (Fig. 20). 
Results (Tab. 7) indicated that there were no significant changes between 
different ratios of α1 to β3 to γ2His8 viruses, ratios of viruses to Sf9 cells (moi) and 
harvesting time points (dpi). All expression levels were around 0.5pmol 
[3H]flunitrazepam. This [3H]flunitrazepam expression level of α1β3γ2His8 was lower than 
the [3H]flunitrazepam level of α1β3His8γ2 GABAA receptors (1-3pmol see Tab. 2 and 
Tab. 3). In contrast [3H]muscimol binding data indicated an expression level around 
2pmol/mg protein. The higher [3H]muscimol than [3H]flunitrazepam expression level 
was also found during α1β3His8γ2 expression (Tab. 4). These data indicated that under 
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the used conditions more receptors composed of α1β3 subunits were formed as 
compared to α1β3γ2 receptors. 
Ratio α1 : β3 : γ2His8 moi dpi pmol [
3
H]flunitrazepam 













































Tab. 7: Optimization of the protein expression of α1β3γ2His8 GABAA receptors in Sf9 cells. Sf9 cells 
were co-infected with different ratios of α1, β3 and γ2His8 subunits and different moi (multiplicity of 
infection). Cells were harvested after 2 or 3 days and membranes were prepared. Receptors were 
incubated with 10nM [
3
H]flunitrazepam ± 100µM diazepam or 40nM [
3
H]muscimol ± 1mM GABA and 
specific binding (pmol [
3
H]flunitrazepam/mg total protein or pmol [
3
H]muscimol/mg total protein) was 
calculated. 
Western blot signals (Fig. 20) of the specifically stained α1, the β3 or the γ2 
subunit did not indicate significant differences in the amount of subunits expressed at 
different ratios of α1 to β3 to γ2His8 viruses, ratios of viruses to Sf9 cells (moi) and 
harvesting time points (dpi). 
The α1 subunit was stained at about 50kDa and showed degradation bands 
overlapping with the signal of the α1 subunit and at a molecular mass of 40kDa. Bands 
stained at 30kDa represented a known unspecific binding of the antibody. The β3 
subunit was stained at the molecular mass of about 50kDa. Degraded subunits were at 
about 40kDa and an unspecific binding of the antibody was observed at 35kDa. The 
γ2His8 subunit at an approximate molecular mass of 50kDa was also degraded, as 
indicated by a strong band at about 40kDa. Bands at higher molecular masses 
indicated aggregates of the subunits, which were not dissolved properly during 
SDS-PAGE. 












1    2    3     4     5     6     7     8
1: α1β3γ2His8 2:1:1   moi 1   2dpi
2: 2:1:1          2   2
3: 3:1:1          1   2
4: 3:1:1        2   2
5: 2:1:1         1   3
6: 2:1:1          2   3
7: 3:1:1          1   3
8: 3:1:1         2   3 
 
Fig. 20: SDS-PAGE and Western blot of various α1β3γ2His8 GABAA receptor expressions. Sf9 cells 
were co-infected with different ratios of α1, β3 and γ2His8 subunits and different moi. Cells were harvested 
after 2 or 3 days, membranes were prepared and the same amount of total protein was subjected to SDS-
PAGE and Western blot analysis. The blots were stained with α1L, β3N and γ2L specific antibodies. 
In spite of the strong degradation of the γ2 subunit we decided to repeat this 
experiment, using a large scale purifying procedure under the assumption that the 
degraded γ2 subunits might not have assembled to intact GABAA receptors. According 
to the latter results, we used a ratio of 3:1:1 with a moi = 1 and harvested the cells after 
2dpi = 50h to produce large amounts of α1β3γ2His8 receptors to purify them via a 
Ni-NTA column. The lower moi (ratio viruses to cells) and harvesting time point was 
chosen to keep the degradation at a minimum. 
3.2.2 Purification with a Ni-NTA column 
For large scale purification with a Ni-NTA column, a pellet of 1200ml harvested 
Sf9 cells, expressing α1β3γ2His8 GABAA receptors was used. This pellet contained 
200pmol [3H]flunitrazepam binding sites corresponding to 50µg receptor protein (see 
Tab. 8). 
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Membranes were prepared from the Sf9 pellet (2.4.1), extracted in 135ml 0.5% 
Triton X-100 extraction buffer (2.4.2) and the clear supernatant applied to a 700µl 
Ni-NTA agarose column. The column was washed with 3ml of a 40mM (W1-W3) 
imidazole buffer and then with 1ml aliquots of a 120mM imidazole buffer (W4). The 
proteins were eluted with 2 x 1ml 250mM imidazole buffer aliquots (E1, E2). 
The yield and the purity of the washing and elution samples were determined 
with PEG precipitation and 10nM [3H]flunitrazepam radioligand binding assay and 
SDS-PAGE with subsequent Coomassie blue staining (Fig. 21) and Western blot 
analysis (Fig. 22). The radioligand binding assay data are summarized in Tab. 8. 
 pmol [
3
H]flunitrazepam binding Calculated µg receptor protein 
Membrane preparation 200 50 
Extract 82 21 






Eluates 2.3 0,6 
Tab. 8: One-step purification of α1β3γ2His8 GABAA receptors with a Ni-NTA column. Sf9 cells were 
co-infected with α1, β3 and γ2His8 subunits and harvested after 3 days. Membranes and extracts were 
prepared and receptors were purified via a Ni-NTA column. Samples from different stages of the 
purification were incubated with 10nM [
3
H]flunitrazepam ± 100µM diazepam and specific binding (pmol 
[
3
H]flunitrazepam) was calculated. 
Even though the extract of a 1200ml Sf9 pellet was applied to a small column, 
the yield was very low (Tab. 8). From 200pmol [3H]flunitrazepam binding only 82pmol 
were measured in the extract, meaning a loss of 60% of receptors in this step and from 
these 82pmol the column retained 15pmol and 2.3pmol were eluted. These 2.3pmol 
corresponded with 0.6µg receptor protein. 














1        2      3      4      5      6      7      8
 
Fig. 21: SDS-PAGE and Coomassie blue staining of the α1β3γ2His8 receptor purification with a 
Ni-NTA column. Sf9 cells were co-infected with α1, β3 and γ2His8 subunits. Membranes and extracts were 
prepared and receptors purified via a Ni-NTA column. Aliquots from different washing (W1-W3: 40mM, 
W4: 120mM imidazole) and elution steps (E1-E2: 250mM imidazole) were precipitated, subjected to SDS-
PAGE and Coomassie blue staining. 
The Coomassie blue staining (Fig. 21) of the purification showed enriched 
bands in the elution steps, but due to the amount of stained bands in these lanes, it 
was not possible to identify the correct bands for the α1, the β3 or the γ2His8 subunits 
(~50kDA). The eluted amount of receptors was too low to detect the GABAA receptor 
subunits with a Coomassie blue staining. The purification was confirmed with a 
Western blot with subunit specific antibodies (Fig. 22). 
In the Western blot of the large scale purification (Fig. 22) the α1, the β3 and the 
γ2His8 subunits were stained specifically at the apparent molecular mass of 50kDa. 
The α1 subunit was found in the first washing step (W1) and in the eluate 1 (E1) 
and eluate 2 (E2). At about 40kDa a degradation band was stained in W4, E1 and E2. 
At 30kDa was an unspecific binding of the antibody. The β3 subunit was stained 
specifically in the first (W1) and fourth (W4) washing and in the two elution steps (E1, 
E2). In these lanes degradation bands at about 45kDa were seen. The other bands at 
the approximate molecular mass of 35kDa were unspecific binding reactions of the 
used β3 antibody. The γ2 subunit was stained specifically in the first (W1) and last (W4) 
washing step and in both elution steps (E1, E2). The bands at 45, 35 and 30kDa 
represented unspecific binding of the used γ2 antibody. Bands at higher molecular 
masses indicated aggregates of the subunits, which were not dissolved properly during 
SDS-PAGE. 
 






















Fig. 22: SDS-PAGE and Western blot of the α1β3γ2His8 receptor purification with a Ni-NTA column. 
Sf9 cells were co-infected with α1, β3 and γ2His8 subunits. Membranes and extracts were prepared and 
receptors purified via a Ni-NTA column. Aliquots from different washing (W1-W3: 40mM, W4: 120mM 
imidazole) and elution steps (E1-E2: 250mM imidazole) were precipitated, subjected to an SDS-PAGE and 
Western blot analysis. The blots were stained with α1L, β3N and γ2L specific antibodies. 
These Western blot results presented a pure α1β3γ2 receptor in the first washing 
step, eluted with 40mM imidazole (lane 3). Unfortunately a lot of other, unspecific 
proteins were also eluted from the column with this low amount of imidazole (Fig. 21). 
The α1β3γ2-receptor in W1 was stained with the specific antibodies, but the amount is 
still too low to stain with coomassie blue. 
The cloning of the His-tag into the γ2 subunit thus showed no improvement in 
the large scale purification via a Ni-NTA column, compared to receptors containing the 
His-tag in the β3 subunit. In addition the GABAA receptor subunits were degraded after 
the expression, especially the γ2 subunit (Fig. 20). Obviously this degradation 
diminished the assembly and expression of α1β3γ2-containing receptors in the Sf9 cells. 
The process of membrane preparation, extraction and purification with a column led to 
very little recovery of α1β3γ2 GABAA receptors in the end. 
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Thus cloning of the His8-tag into the γ2 subunit did not enhance the yield for the 
planned crystallization experiments. 
The low yield of receptors might also be explained by the possibility that a 
single Sf9 cell was not infected simultaneously with all three subunits (α, β and γ 
viruses) thus reducing the formation of functional α, β and γ-containing receptors. To 
enhance the possibility that each cell was infected with all three subunits, the next 
experimental approach was to clone all three subunits into one vector, to obtain a 
baculovirus infecting a cell with all three subunits. In addition a His12-tag (two times 6 
Histidines) was cloned into the γ2 subunit to increase the binding of the receptor to a 
Ni-NTA column. This also should allow washing the column with higher concentrations 
of imidazole. 
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3.3 α1β3γ2His12 GABAA receptors 
The previous experiments showed several problems in the generation of high 
expression levels of non-degraded α1β3γ2-containing GABAA receptors. Receptors 
containing the His-tag on the β3 subunit had an acceptable expression level but were 
difficult to purify and the loss of receptors during a two-step purification was huge. Due 
to the heterogeneity of purified receptors (β3His8, α1β3His8 and α1β3His8γ2) they could 
not be used for further crystallization experiments. Receptors containing the His-tag on 
the γ2 subunit did not reach an expression level in the picomolar range, which would 
have been necessary for further structural analysis. 
Another explanation for the low expression level and/or the degradation of a 
subunit was that both experimental setups were done with three different viruses. The 
chance that a cell was infected by all three viruses at the same time probably was very 
small. Consequently the next step was to clone all three subunits into one vector. With 
this method it should be ensured that an infected Sf9 cell contained all three subunit 
DNAs to express α1β3γ2His12 receptors. 
3.3.1 Cloning of the triple construct α1β3γ2His12 
In order to reduce the size of the plasmid for the subsequent cloning steps, the 
promoter region of the plasmid pBAC4x-1 was cloned into pUC18. After sequential 
insertion of an alpha1, a beta3 and a gamma2 subunit the completed insert was cloned 
back into the pBAC4x-1. 
The correct DNA sequence was checked in all following cloning steps. 
3.3.1.1 Cloning of the promoter region from pBAC4x-1 into pUC18 
pBAC4x-1 (Fig. 23) is a baculovirus transfer plasmid designed for cloning and 
co-expression of up to four target genes in insect cells. The plasmid contains two polh 
promoters and two p10 promoters, each of which is upstream of unique cloning sites 
for sequential insertion of target genes. The homologous promoters are in opposite 
orientation to minimize recombination. 
Insert: pBAC4x-1 was cut with the restriction enzymes EcoRI (1238) and 
HindIII (1947). The resulting DNA fragment (709bp) contained the polylinker region with 
two polh promoters and two p10 promoters (Fig. 23). 
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Fig. 23: Generation of the insert for cloning of the promoter region from pBAC4x-1 into pUC18. 
Vector: pUC18 was cut with the restriction enzymes HindIII and EcoRI and the 
insert from pBAC4x-1 was cloned into the remaining vector, resulting in the construct: 
p10-polh-pUC18 (Fig. 24) (3345bp). 
Construct: p10-polh-pUC18: 
 
Fig. 24: Final construct after cloning of the promoter region from pBAC4x-1 into pUC18. 
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3.3.1.2 Mutagenesis of the alpha1 subunit and cloning of the 
mutated alpha1 into p10-polh-pUC18 
Using Gene SOEing technique (see 2.1.8.1) a BclI site was introduced 
upstream of the alpha1-CDS (coding sequence) and the BamHI site between TM3 and 
TM4 was deleted (silent mutation). 
The resulting DNA fragment (insert) was cut with BclI and EcoRI (Fig. 25) and 
ligated into the vector p10-polh-pUC18, which was cut with BglII (1104) and EcoRI 
(1110) (Fig. 26), thereby generating the construct alpha1mut-p10-polh-pUC18#12 
(4848bp) (Fig. 27). The restriction enzymes BclI (insert) and BglII (vector) generate 
compatible cohesive ends. 
Insert: 
 
Fig. 25: Schematic drawing of the mutated alpha1 subunit used for cloning into p10-polh-pUC18. 
Vector p10-polh-pUC18: 
 
Fig. 26: Schematic drawing of the vector p10-polh-pUC18 used for cloning of the mutated alpha1 
subunit. 




Fig. 27: Map of the final construct after cloning of the mutated alpha1 subunit into p10-polh-pUC18. 
3.3.1.3 Mutagenesis of the beta3 subunit and cloning of the 
mutated beta3 into α1mut-p10-polh-pUC18 
In order to prepare the beta3 subunit for the following cloning steps, four 
restriction sites were deleted without any change in the protein sequences of this 
subunit. Using Gene SOEing technique (see 2.1.8.1) the restriction sites for BamHI 
(318) and EcoRI (1183) in the coding sequence of the beta3 subunit and the restriction 
sites for EcoRI (1576) and NotI (1569) in the 3’-untranslated region of the beta3 subunit 
were deleted (Fig. 28). 
The resulting DNA fragment beta3-mut CDS (insert) was cut with XbaI and 
EcoRV and ligated into the vector alpha1mut-p10-polh-pUC18#12 cut with XbaI (848) 
and StuI (855) (Fig. 29) thereby generating the construct alpha1-beta3-p10-polh-
pUC18#9 (Fig. 30). The enzymes EcoRV (insert) and StuI (vector) generate blunt ends. 








Fig. 29: Map of the vector α1mut-p10-polh-pUC18 used for cloning of the mutated beta3 subunit. 




Fig. 30: Map of the construct after cloning of the mutated beta3 subunit into 
α1mut-p10-polh-pUC18. 
3.3.1.4 Mutagenesis of the gamma2 subunit and cloning of the 
mutated gamma2 into α1-β3-p10-polh-pUC18 
3.3.1.4.1 The mutagenesis of the gamma2 subunit was performed in 
three steps. 
1. Introduction of a Tobacco Etch Virus (TEV) protease recognition site. Using 
Gene SOEing technique (see 2.1.8.1) the TEV protease recognition site was 
introduced into the gamma2-His8 CDS between amino acid 23 and 24 of the 
mature protein. 
Resulting sequence (only the N-terminus of the mature protein is shown): 
aa1-4-His8-FactorXa-aa1-23-TEV-aa24…. 
2. Introduction of a double-hexa-His tag at the N-terminus. Using Gene SOEing 
technique (see 2.1.8.1) a double-hexa-His tag was introduced into the 
gamma2-His8-TEV (step 1) construct between aa4 and 5 of the mature protein. 
Resulting sequence (only the N-terminus of the mature protein is shown):  
aa1-4-His6-11 amino acid spacer-His6-aa5-23-TEV-aa24…. 
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3. Modification of restriction sites. To avoid a fragmentation of the gamma2 subunit 
by the restriction enzyme EcoRI in a later cloning step, the restriction site for EcoRI 
(740) in the protein coding sequence was deleted (silent mutation) by using Gene 
SOEing technique (see 2.1.8.1). The restriction sites for XbaI (1526), SalI (1532) 
and NotI (1543) in the 3’-UTR were deleted and replaced with a BamHI site (1561) 
(Fig. 31). 
Resulting insert: gamma2-His12-TEV-mut-CDS (Fig. 32). 
Insert: 
 
Fig. 31: Schematic drawing of the gamma2 subunit before mutagenesis. 
 
 
Fig. 32: Schematic drawing of the mutated gamma2 subunit used for cloning into 
alpha1-beta3-p10-polh-pUC18#9. 
3.3.1.4.2 Cloning of the mutated gamma2 subunit into alpha1-beta3-
p10-polh-pUC18#9 
The plasmid alpha1-beta3-p10-polh-pUC18#9 was cut with the restriction 
enzymes SpeI (596) and BamHI (409) (Fig. 33). The resulting DNA fragment used as 
vector had a size of 6141bp. Using this combination of restriction enzymes the second 
polh promoter not used for further cloning steps was deleted. 
Results  Katharina Grote 
74 
The insert gamma2-His12-TEV-mut-CDS was cut with the restriction enzymes 
NheI (33) and BamHI (1561) (Fig. 32). The resulting DNA fragment had a size of 
1528bp. The resulting construct a1-b3-g2-His12-p10-polh-pUC18 had a size of 7669bp 
(Fig. 34). 
 




Fig. 34: Map of the final construct after cloning the mutated gamma2 subunit into alpha1-beta3-
p10-polh-pUC18#9. 
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3.3.1.5 Subcloning of the α1-β3-γ2His12 construct into pBAC4x-1 
The final insert encoding the three receptor subunits alpha1, beta3 and 
gamma2-His12 was cut out of the pUC18 vector with the restriction enzymes BamHI 
(409) and EcoRI (5434) (Fig. 35) and ligated into the similarily cut transfer vector 
pBAC4x-1 (Fig. 36). 
The resulting plasmid construct a1-b3-g2-His12-pBAC4x-1 had a size of 
10242bp (Fig. 37). 
Insert: 
 
Fig. 35: Generation of the insert for subcloning of the α1-β3-γ2His12 construct into pBAC4x-1. 
Vector pBAC4x-1: 
 
Fig. 36: Map of the vector pBAC4x-1 used for subcloning of the α1-β3-γ2His12 insert. 




Fig. 37: Map of the final construct after subcloning of the α1-β3-γ2His12 DNA fragment into 
pBAC4x-1. 
3.3.2 Determination of the optimal conditions for the 
expression of α1β3γ2His12 GABAA receptors 
Before starting large scale expression and purification experiments of 
α1β3γ2His12 GABAA receptors via a Ni-NTA column, optimal expression conditions with 
a high expression level and little degradation had to be determined (Tab. 9). For that, 
different multiplicities of infection (moi) and different harvesting times (dpi) were tested. 
Sf9 cells were harvested after 2 and 3dpi. Membranes from harvested Sf9 cells 
were suspended in a Tris/Citrate buffer (2.3.1) and radioligand binding assays with 
10nM [3H]flunitrazepam or 40nM [3H]muscimol were performed (2.3.3, 2.3.2) (Tab. 9). 
In addition to the binding assay experiments, the samples were also tested for 
degradation of receptors with SDS-PAGE and Western blot experiments (2.6) (Fig. 38). 
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moi dpi pmol [
3
H]flunitrazepam 





























Tab. 9: Optimization of the protein expression of the triple construct α1β3γ2His12 in Sf9 cells. Sf9 
cells were infected with the α1β3γ2His12 virus with different moi (multiplicity of infection). Cells were 
harvested after 2 or 3 days and membranes were prepared. Receptors were incubated with 10nM 
[
3
H]flunitrazepam ± 100µM diazepam or 40nM [
3
H]muscimol ± 1mM GABA and specific binding (pmol 
[
3
H]flunitrazepam/mg total protein or pmol [
3
H]muscimol/mg total protein) was calculated. 
Results (Tab. 9) indicated that there were no significant changes between 
different ratios of viruses to Sf9 cells (moi) and harvesting time points (dpi). All 
conditions showed a very low expression level 0.5pmol [3H]flunitrazepam/mg total 
protein or 0.3pmol [3H]muscimol/mg total protein. Unfortunately, these values lie below 
the 2pmol/mg range necessary for purification of the receptor for further structural 
analysis experiments. 
The [3H]flunitrazepam binding of 0.5pmol/mg total protein was comparable to 
the results of the single viruses expressing the α1β3γ2His8 construct (Tab. 7). In 
contrast, a much lower [3H]muscimol binding expression level was obtained with the 
triple construct (0.3pmol) than with the α1β3γ2His8 construct (2pmol). 
This low expression level of the α1β3γ2His12 receptor was also seen in the 
performed SDS-PAGE and Western blot, where α1L, β3N or γ2L specific antibodies were 
used. The different expression conditions showed nearly the same band intensity and 
degradation pattern (Fig. 38). 
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1: moi 0.5  2dpi
2:        0.5  3
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Fig. 38: SDS-PAGE and Western blot of various α1β3γ2His12 expression conditions in Sf9 cells. Sf9 
cells were infected with the α1β3γ2His12 virus and different moi (multiplicity of infection). Cells were 
harvested after 2 or 3 days, membranes prepared and the same amount of total protein was subjected to 
SDS-PAGE and Western blot. The blots were stained with α1L, β3N and γ2L specific antibodies. 
The α1 subunit, at an apparent molecular mass of 50kDa, was expressed quite 
well with a strong degradation between 45-50kDa. All other stained bands in this blot 
were cross-reactivity stainings of the used antibody. In contrast the β3 subunit at about 
50kDa was expressed only to a very low extent, compared to previous β3 expression 
experiments. Degraded proteins of this weakly expressed subunit were stained below 
50kDa by the antibody. The γ2 subunit, visible as a strong band at the molecular mass 
of about 48kDa was also degraded (strong band at 40kDa). Bands at higher molecular 
masses indicated aggregates of the subunits, which were not dissolved properly during 
SDS-PAGE. 
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3.3.3 Purification with a Ni-NTA spin column 
When the results shown in Tab. 9 and Fig. 38 were obtained, already large 
amounts of α1β3γ2His12 receptors had been expressed. Although the determination of 
the optimal conditions showed degradation of the subunits in the membrane, we 
started purification experiments anyway, hoping that only non-degraded, functional 
α1β3γ2His12 receptors, with a non-degraded His-tag on the γ2 subunit would be 
assembled and bound to the Ni-NTA column. By using a large scale expression we 
hoped that the amount of lost receptors could be balanced. 
To determine optimal expression conditions, a preliminary experiment with a 
small amount of cells for a Ni-NTA spin column purification was performed (2.4.3.1). 
Therefore a pellet of 170ml Sf9 cells, expressing α1β3γ2His12 receptors was used. This 
pellet contained 25pmol [3H]flunitrazepam binding sites corresponding to 6µg receptor 
protein. 
Membranes were isolated from the Sf9 pellet (2.4.1), extracted in 8ml 0.5% 
Triton X-100 extraction buffer (2.4.2) and the clear supernatant was applied to a 
Ni-NTA spin agarose column (600µl aliquots) (2.4.3.1). The column was washed twice 
with 600µl of a 40mM imidazole buffer and then with 600µl of an 80mM imidazole 
buffer. The proteins were eluted with 2 x 200µl 250mM imidazole buffer aliquots 
(eluates 1 and 2). The samples were tested with SDS-PAGE and Coomassie blue 
staining (Fig. 39) and Western blot analysis (Fig. 40) for degradation. 
The Coomassie blue staining (Fig. 39) showed a variety of stained bands in all 
washing and elution samples. There seemed to be no purification of the receptor, 
indicated normally by a loss of bands in the flow through or an increase of bands at the 
expected molecular mass in the lanes, containing the eluates. Alternatively too little 
receptor protein was loaded on the SDS-PAGE to be detected with Coomassie blue 
staining. 
Therefore a Western blot with the same samples was performed, to check for a 
purification of at least a minimum of receptor (Fig. 40). An α1 and a γ2 specific antibody 
were used. The β3 subunit was not investigated, because at this point we were only 
interested in the amount of α and γ subunits, as a measure for α1β3γ2-subunit 
containing receptors. 














Fig. 39: SDS-PAGE and Coomassie blue staining of an α1β3γ2His12 receptor purification with a 
Ni-NTA spin column. Sf9 cells were co-infected with the α1β3γ2His12 virus. Membranes and extracts were 
prepared and receptors purified via a Ni-NTA spin column. Aliquots from different washing (W1-W2: 40mM 
imidazole) and elution steps (E1-E2: 250mM imidazole) were precipitated, subjected to an SDS-PAGE and 
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Fig. 40: SDS-PAGE and Western blot of the α1β3γ2His12 receptor purification with a Ni-NTA spin 
column. Sf9 cells were co-infected with the α1β3γ2His12 virus. Membranes and extracts were prepared 
and receptors purified via a Ni-NTA column. Aliquots from different washing (W1-W2: 40mM imidazole) 
and elution steps (E1-E2: 250mM imidazole) were precipitated, subjected to an SDS-PAGE and Western 
blot. The blots were stained with α1L and γ2L specific antibodies. 
In the Western blot the α1 subunit was detected in all samples at the apparent 
molecular mass of 50kDa. The α1 antibody stained cross-reactivities at the molecular 
mass of 20, 25 and 35kDa as well. The γ2 subunit was only detected in the extract 
(lane1), the flow through (lane 2) and in both eluates (lane 5 and 6) at the apparent 
molecular mass of 48kDa. 
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These results indicated that only small amounts of α1β3γ2His12 GABAA 
receptors were expressed, that were only detectable with a Western blot (Fig. 40), but 
not in Coomassie blue staining (Fig. 39). This implied the necessity to use more 
material for the next purification experiment and the requirement of a minimum of 
expressed receptors for adequate purification. 
3.3.4 Purification with a Ni-NTA column 
A pellet of 510ml harvested Sf9 cells, expressing α1β3γ2His12 GABAA receptors 
was used. This pellet contained 79pmol [3H]flunitrazepam binding sites corresponding 
to 20µg receptor protein. 
Membranes were prepared from the Sf9 pellet (2.4.1), extracted in 120ml 0.5% 
Triton X-100 extraction buffer (2.4.2) and the clear supernatant applied to a 750µl Ni-
NTA agarose column. The column was washed with 4ml of a 40mM imidazole buffer 
and then with 3 x 700µl aliquots of an 80mM imidazole buffer. The proteins were eluted 
with 5 x 700µl 250mM imidazole buffer aliquots (eluate 1-5). The samples were tested 
with SDS-PAGE, Coomassie blue staining (Fig. 41) and Western blot analysis (Fig. 
42). In addition a [3H]flunitrazepam PEG precipitation assay was performed from the 
washing and the first 3 elution samples (Tab. 10). 






Fig. 41: SDS-PAGE and Coomassie blue staining of α1β3γ2His12 receptors purification with a 
Ni-NTA column. Sf9 cells were infected with the α1β3γ2His12 virus. Membranes and extracts were 
prepared and receptors purified via a Ni-NTA column. Aliquots from different washing and elution steps 
were precipitated, subjected to SDS-PAGE and stained with Coomassie blue. 
The Coomassie blue staining showed no signals for the purified α1β3γ2His12 
GABAA receptor subunits. The α1, the β3 and the γ2His12 subunits should exhibit a 
protein band at the apparent molecular mass of 50, 50 and 48kDa, respectively. All 
bands, stained in the Coomassie blue staining were unspecific proteins from the 
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extract. The strong band at about 48kDa, seen in the washing step with 80mM 
imidazole, was already detected in previous experiments and did not represent a 
GABAA receptor subunit (Fig. 18). An adequate purification level was not reached with 
the low expression level of receptors. 
To confirm that at least small amounts of α1, β3 and γ2His12 were expressed 
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Fig. 42: SDS-PAGE and Western blot of α1β3γ2His12 receptors purification with a Ni-NTA column. 
Sf9 cells were infected with the α1β3γ2His12 virus. Membranes and extracts were prepared and receptors 
purified via a Ni-NTA column. Aliquots from different washing (W1: 40mM; W2-W4: 80mM imidazole) and 
elution steps (E1-E2: 250mM imidazole) were precipitated, subjected to an SDS-PAGE and Western blot. 
The blots were stained with α1L, β3N and γ2L specific antibodies. 
In the Western blot the α1, β3 and γ2His12 subunits were stained at the apparent 
molecular mass in the washing (80mM imidazole) and elution (250mM imidazole) 
samples. The α1 (50kDa) and the γ2His12 (48kDa) subunits indicated no degradation, 
whereas the β3 subunit (50kDa) showed degraded protein bands at the molecular mass 
of 45kDa. This degradation could have caused the low expression level. Functionally 
assembled GABAA receptors need intact β subunits. 
This result indicated that the α1β3γ2His12 GABAA receptors were already eluted 
from the column, starting with 80mM imidazole. At this low amount of imidazole, other 
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proteins from the extract, bound to the Ni-NTA column, were eluted as well. This 
problem resulted from the His-tag on the γ subunit, which is present in an α1β3γ2 
receptor only once. The double His6-tag in the α1β3γ2His12 GABAA receptors could not 
enhance the binding affinity to the Ni-NTA column. A His-tag on the β3 subunit, which is 
present twice in an α1β3γ2 receptor, resulted in a stronger binding of the receptor to the 
column. Therefore the column could be washed more stringently and the receptor was 
eluted at a higher imidazole concentration (Fig. 18). 















Tab. 10: One-step purification of α1β3γ2His12 GABAA receptors with a Ni-NTA column. Sf9 cells were 
infected with the α1β3γ2His12 virus. Membranes and extracts were prepared and receptors purified via a 
Ni-NTA column. Samples from different stages of the purification (washing (W1: 40mM; W2-W4 80mM: 
imidazole and elution steps E1-E2: 250mM imidazole) were incubated with 10nM [
3
H]flunitrazepam ± 
100µM diazepam and specific binding (pmol [
3
H]flunitrazepam) was determined. 
The performed [3H]flunitrazepam binding assay data (Tab. 10), using the same 
washing and elution samples, confirmed the results from the Coomassie blue staining 
(Fig. 41) and the Western blot (Fig. 42). Most of the α1β3γ2His12 GABAA receptors 
were eluted with 80mM imidazole (washing 2 and 3). At this low imidazole 
concentration other bound proteins from the extract to the Ni-NTA column were eluted 
as well and thereby contaminating the receptor samples for further structural analysis. 
3.3.5 Expression and characterization of α1β3γ2His12 
receptors plus additional β3 
The low expression level and the degraded β3 subunit led to the assumption 
that the β3 subunit was not expressed in the correct manner in the triple construct to 
form functional α1β3γ2-containing receptors in Sf9 cells. Therefore in the next 
expression experiments, the triple construct viruses were co-infected with additional β3 
viruses in Sf9 cells. 
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Membranes from harvested Sf9 cells were prepared (2.3.1) and a radioligand 
binding assays with 10nM [3H]flunitrazepam (2.3.3) was performed (Tab. 11). Sf9 cells 
were harvested after 2 days. In addition to the binding assay experiments, the samples 
were also tested for degradation of receptors with SDS-PAGE and Western blot 
analysis (2.6) (Fig. 43). 
Additional β3 viruses dpi pmol [
3












H]flunitrazepam binding assay of an α1β3γ2His12 plus additional β3 virus expression. Sf9 
cells were co-infected with a constant amount of α1β3γ2His12 virus and increasing amount of β3 virus and 
harvested after 2 days. Membranes and extracts were prepared and incubated with 10nM 
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Fig. 43: SDS-PAGE and Western blot of an α1β3γ2His12 plus additional β3 viruses expression. Sf9 
cells were infected with a constant amount of α1β3γ2His12 virus and increasing amount of β3 virus. 
Membranes were prepared and the same amount of total protein was subjected to an SDS-PAGE and 
Western blot. The blots were stained with α1L, β3N and γ2L specific antibodies. 
This binding assay experiment (Tab. 11) indicated that the expression level of 
the α1β3γ2His12 GABAA receptor could not be enhanced by additionally added β3 
viruses. The same expression level of 0.5pmol [3H]flunitrazepam binding/mg total 
protein was observed under the conditions where the α1β3γ2His12 triple construct virus 
was used alone (Tab. 9). 
SDS-PAGE and Western blot experiments (Fig. 43) indicated that the β3 subunit 
was much stronger expressed due to the additional recombinant β3 viruses, but the 
expression levels of the α1 and γ2 subunits were not enhanced in the Sf9 membrane 
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(compare with Fig. 38). This showed that the cells were infected with the additional β3 
viruses but instead of assembling more α1β3γ2 receptors, homooligomeric β3 receptors 
were expressed. 
The α1 subunit at the apparent molecular mass of 50kDa was degraded. The 
degradation products were stained at 45 and 48kDa. The bands at around 35kDa were 
cross-reactions of the antibody. The strong signal of the β3 subunit at 50kDa showed 
no degradation, but the β3 antibody showed cross-reactivities between 15 and 40kDa. 
Most of the γ2 subunits were degraded and stained at the apparent molecular mass of 
40kDa, whereas the non-degraded γ2 at 48kDa could be hardly detected. Bands at 
higher molecular masses indicated aggregates of the subunits, which were not 
dissolved properly during SDS-PAGE. 
By co-infecting Sf9 cells with the α1β3γ2His12 triple construct and β3 alone it 
seemed that all three subunits showed stronger degradation in the Western blot (Fig. 
43) compared to the α1β3γ2His12 triple construct alone (Fig. 40). 
For further structural analysis an expression of a minimum of 2 picomol pure 
receptor/mg protein is required. This is the approximate value of the amount of existing 
GABAA receptors in the brain. At the moment this expression value could not be 
reached with the triple construct virus, expressing α1β3γ2His12 GABAA receptors. 
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3.4 Future prospects 
The three different experimental setups to express and purify large amounts of 
α1β3γ2 GABAA receptors indicated that the first approach with α1, β3His8 and γ2 
recombinant viruses and a two-step purification resulted in the largest amount of highly 
purified α1β3γ2 receptors (Fig. 19). However, using these conditions only 3% of the 
generated receptor could be purified. It is thus questionable whether the method can 
be up-scaled sufficiently to obtain large amounts of purified receptor required for 
crystallization trials. 
Nevertheless large scale expression of this virus combination in Sf9 cells is 
currently performed for a different purpose. After purification, the receptor will be 
separated on a BN/SDS-PAGE. The group of Professor Lubec, Vienna is going to pick 
spots from the gel, make an in-gel digestion and identify the proteins and their 
sequence with qQTOF. The sequence of the alpha1 and the beta3 subunit has already 
been published with this method (Kang et al. 2008; Kang and Lubec 2009). Therefore 
this group will concentrate on sequencing the gamma2 subunit. 
Knowing also the sequence of the gamma2 GABAA receptor subunit, it is 
planned to investigate drug-binding sites at the α1γ2 interface of these receptors, 
identified by photoaffinity labeling of the receptors with suitable drugs. In addition, it is 
planned to investigate whether purified α1β3His8γ2 GABAA receptors could be used for 
surface plasmon resonance studies performed by a collaborating group. 
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4 DISCUSSION 
GABAA receptors are targets for many clinically important drugs that influence 
excitability of the brain, motor function, anxiety, cognition, vigilance and memory 
(Sieghart 1995). The exact molecular structure of the GABAA receptor, however, is still 
unknown, as it is the case for most receptors of the cys-loop receptor super-family. 
Aim of this thesis was to produce recombinant hetero-oligomeric (alpha1-beta3-
gamma2) GABAA receptors for subsequent structural analysis, such as crystallization, 
photo affinity labeling or surface plasmon resonance investigations. 
The α1β3γ2 receptors were expressed in the baculovirus expression system, 
which has become one of the most widely used systems for routine production of 
recombinant proteins. The baculovirus expression system has the advantages of 
eukaryotic posttranslational modifications and an easy and safe to use virus and cell 
culture system. 
This thesis is based on the results of the thesis ―High yield expression and His-
tag purification of recombinant GABAA receptors using Sf9-baculovirus Expression 
Vector System‖ from Leila Wabenegger. Single-construct viruses used in my thesis 
were already cloned and had to be amplified to working stocks and characterized with 
virus PCR and virus plaque assay experiments. 
It was already published that expression of GABAA receptors consisting of a 
single α1, β1 or γ2 subunit or dual combinations of α1γ2, β1γ2 or β3γ2 did not lead to the 
formation of functional ion channels or binding sites (Hartnett et al. 1996). Functional 
homo-oligomeric GABAA receptors can only be formed by the β3 subunit. This receptor 
type has a binding pocket for several insecticides, such as α-endosulfan or lindane and 
can be detected with [3H]EBOB binding studies (Ratra and Casida 2001; Kang and 
Lubec 2009). Sf9 cells infected with α1 and β3 or α1, β3 and γ2 subunits produced 
homo-oligomeric β3, recombinant hetero-oligomeric α1β3 or α1β3γ2 GABAA receptors. 
The GABA binding pocket between an alpha and a beta subunit was measured with 
[3H]muscimol, whereas the benzodiazepine binding pocket between a beta and a 
gamma subunit was measured with a [3H]benzodiazepine, such as Ro15-1788 or 
flunitrazepam. These binding assay results also demonstrated that GABAA receptors 
were functionally expressed by the baculovirus expression system (Hartnett et al. 
1996).  
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In this thesis three different α1β3γ2 receptor types, which differ in the subunit 
composition, the additional His-tag and in the amount of baculovirus required to infect a 
single cell with all three subunits, were expressed, purified and characterized. The first 
experiments were performed with α1, β3His8, and γ2 viruses. For the second co-
infection α1, β3 and γ2His8 viruses were used and the third receptor type was formed in 
Sf9 cells infected with a single virus containing the α1, β3, and γ2His12 subunits. 
For large scale expression experiments huge amounts of viruses were needed. 
Therefore the existing virus stocks of α1, β3His8, γ2 and γ2His8 viruses were scaled up 
to working stocks and the virus titer was determined with virus plaque assay 
experiments. The virus stock had to reach a minimum of 1x107 viruses/ml serum to be 
stable during storage and to infect Sf9 cells with a reliable probability. This meant a 
series of amplification experiments to obtain the best virus titer for each used virus. 
In the first experiments α1, β3His8 and γ2 viruses were used for co-infection of 
Sf9 cells to form α1β3His8γ2 GABAA receptors. The ideal harvesting time point of the 
Sf9 cells was determined by Western blot analysis and [3H]flunitrazepam binding 
assays, presenting a high expression level of the receptors between 36 hours (1.5 days 
past infection (dpi)) and 72 hours (3dpi). This result confirmed the expression of the 
subunits under a late promoter. It seemed that the expression level of functional 
receptors could not be additionally enhanced by time, whereas the intensity of the 
degradation could not be diminished by harvesting the cells at a much earlier time 
point. 
Knowing the appropriate harvesting time point, the best ratio of α1 to β3His8 to 
γ2 viruses and the multiplicity of infection (moi) were investigated with [
3H]flunitrazepam 
binding assays. The used ratios of 2:1:1 and 3:1:1 and the moi of 1 and 2 showed no 
significant difference in the receptor expression level. Approximately 2pmol α1β3His8γ2 
GABAA receptors were expressed. For further expressions a ratio of 2:1:1 or 3:1:1 with 
a moi of 1 and a harvesting time point of 72 hours (3dpi) were used. 
After optimization of expression and extraction conditions, α1β3His8γ2 receptors 
could be purified with a Ni-NTA column via the His-tag on the β3 subunit. Approximately 
30% of the applied receptors were eluted. [3H]flunitrazepam and [3H]muscimol binding 
assays indicated a disequilibrium of α1β3γ2 to α1β3-containing receptors. Only about 
10% of the expressed GABAA receptors contained a γ subunit. On the one hand the 
purification indicated a loss of 2/3 of the receptor but on the other hand 1/3 of the 
receptor could be purified quite well and concentrated in a small volume. Binding 
assays and a Western blot and Coomassie blue staining indicated that more β3His8 
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homo-oligomeric and α1β3His8 hetero-oligomeric receptors than the wanted α1β3His8γ2 
GABAA receptors were expressed and subsequently purified with the Ni-NTA column. 
This heterogeneous mixture of receptors cannot be used for crystallization 
experiments. To avoid enrichment of β3His8 homo-oligomeric and α1β3His8 hetero-
oligomeric receptors and to enhance the purity of α1β3His8γ2 receptors a two-step 
purification with a benzodiazepine affinity column and a subsequent Ni-NTA column 
was performed with a large amount of extracted proteins. The benzodiazepine column 
retained all alpha- and gamma-containing receptors, which were concentrated with the 
second column afterwards. Coomassie blue staining from the eluates after the 
benzodiazepine and the Ni-NTA column indicated a well stained, concentrated receptor 
with an estimated purity of 90%. This two-step purification, compared to the single 
Ni-NTA column purification, resulted again in a large loss of receptor. From the applied 
700µg receptor protein, 20µg of pure receptor protein were eluted at the end. In 
principle, this pure receptor could be used for further analysis, but the amount was 
quite low. 
Purification with two columns required a large amount of infected Sf9 cell 
material to obtain a useable, pure and functional amount of receptor at the end of the 
purification for further structural analysis. To overcome this problem a new series of 
co-infection of Sf9 cells was started. This time the His-tag was attached to the γ2 
subunit. The Sf9 cells, infected with α1, β3 and γ2His8 baculoviruses should assemble 
and express α1β3γ2His8 GABAA receptors that then could be purified via the Ni-NTA 
column. Even if β3 homo-oligomeric and α1β3 hetero-oligomeric receptors were also 
assembled and expressed, they could not bind to the Ni-NTA column, thus the binding 
sites at the column should be occupied with α1β3γ2His8 receptors only. 
Once again the best parameters for the expression had to be determined. In 
several experiments the ratio of α1 to β3 to γ2His8, different multiplicities of infection 
(moi) and the best harvesting time point (dpi) were tested. [3H]flunitrazepam and 
[3H]muscimol binding assays indicated very low expression levels and the presence of 
a heterogeneous mixture of α1β3 and α1β3γ2 GABAA receptors. The expression did not 
change when different virus ratios, moi or harvesting time points were used. The 
[3H]flunitrazepam binding was around 0.5pmol/mg total protein. 
Western blot analysis also showed no significant differences in the intensity of 
the bands at the different virus ratios, moi and harvesting time points. The γ2 subunit 
was degraded strongly under all conditions used. This degradation explained the low 
expression level of α1β3γ2His8 receptors, because a lack of functional γ2 could lead to 
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an increase of α1β3 and β3 receptors. However, from these results it was concluded that 
a ratio of 3:1:1 with a moi = 1 and harvesting after 2dpi = 50h should be used for large 
scale expression. 
Under the assumption that the degraded γ2 subunit might not have assembled 
to intact GABAA receptors, we decided to start purification experiments with large 
amounts of extracted receptors. After optimization of expression and extraction 
conditions for the α1β3γ2His8 receptors, they could be purified by a Ni-NTA column via 
the His-tag on the γ2 subunit. [
3H]flunitrazepam binding assays showed a very low yield 
of GABAA receptors. Almost the total amount of receptors was lost during washing of 
the Ni-NTA column. From 82pmol applied receptor protein, 15pmol were retained and 
2.3pmol were eluted. Thus, the column retained approximately 20% of the applied 
receptor protein, but only 3% were eluted after washing. The low amount of eluted 
receptor could not be identified clearly in the Coomassie blue staining, but it could be 
detected by Western blot analysis, showing less degradation of the eluted receptors. 
The use of γ2His8 baculoviruses showed a reduced overall expression of the 
receptor and no improvement in the large scale purification via a Ni-NTA column, 
compared to receptors containing the His-tag in the β3 subunit. The degradation of the 
γ2 subunit further diminished the assembly and expression of functional α1β3γ2-
containing receptors in Sf9 cells. The process of membrane preparation, extraction and 
purification with a single Ni-NTA column led to very little recovery of α1β3γ2 GABAA 
receptors in the end. 
A low expression could also have been caused by the low probability that a 
single Sf9 cell was infected with all three subunits (α, β and γ viruses) to form 
functional α1β3γ2 receptors. To enhance the possibility that each cell was infected with 
all three subunits the next experimental approach was to clone all three subunits into 
one vector, to obtain a baculovirus able to infect a cell with all three subunits. In 
addition a His12-tag (two times 6 Histidines) was cloned into the γ2 subunit to increase 
the binding strength of the receptor to a Ni-NTA column. This should provide the 
opportunity to wash the column with higher concentrations of imidazole. 
All three subunits were cloned into a pBAC4x-1 vector. The plasmid contains 
two polh and two p10 promoters; each of which is upstream of unique cloning sites for 
sequential insertion of target genes. The homologous promoters are in opposite 
orientation to minimize recombination. In order to reduce the size of the plasmid for 
subsequent cloning steps, the promoter region of the plasmid pBAC4x-1 was cloned 
into pUC18. After sequential insertion of an alpha1, a beta3 and a gamma2 subunit the 
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completed insert was cloned back into the pBAC4x-1 vector, resulting in a 10242bp 
large triple construct. 
For preliminary and large scale expression experiments a large amount of virus 
was needed. For that Sf9 cells were transfected with the triple construct to produce 
recombinant viruses. After reaching a functional initial virus stock of α1β3γ2His12 
viruses, they were scaled up to working stocks and the virus titer was determined with 
virus plaque assay experiments after every step. 
When a certain amount of virus working stock was reached, preliminary 
experiments with this new virus were performed. The best expression parameters, 
meaning the moi and the harvesting time point, were determined in several expression 
experiments. [3H]flunitrazepam and [3H]muscimol binding assays indicated very low 
expression levels, below the picomolar range. The [3H]flunitrazepam binding was 
approximately 0.5pmol and the [3H]muscimol binding around 0.3pmol per mg total 
protein for all conditions. These values were approximately in the same range and 
implied that a lot of receptors contained a gamma subunit. Even though the expression 
level was very low, the fact that a lot of receptors contained a gamma subunit was very 
positive. In addition the binding of [3H]flunitrazepam and [3H]muscimol indicated 
functionally expressed receptors, containing the benzodiazepine as well as the GABA 
binding pocket. The expressed 0.5pmol α1β3γ2His12 receptors were comparable with 
the expressed amount of α1β3γ2His8 receptors. Additionally performed Western blots of 
the same samples indicated degradation of all three subunits. This degradation could 
have caused the low amount of functionally expressed α1β3γ2His12 receptors. 
To optimize extraction and purification conditions a small amount of the newly 
expressed α1β3γ2His12 receptor was purified with a Ni-NTA spin column and a 
Coomassie blue staining and a Western blot of the washing and elution samples was 
performed. No enhanced bands at the expected molecular masses were stained. This 
preliminary experiment indicated that we were not able to purify the receptor with a 
Ni-NTA spin column with the His12-tag on the γ2 subunit. 
Although the determination of the optimal conditions showed degradation of the 
subunits in the membrane, we started purification experiments, hoping that only non-
degraded, functional α1β3γ2His12 receptors, with a non-degraded His-tag on the γ2 
subunit would be assembled and bound to the Ni-NTA column. By using a large scale 
expression we hoped that the amount of lost receptors could be balanced. Therefore a 
large batch of α1β3γ2His12 receptors was purified with a Ni-NTA column. A Western 
blot of the washing and the elution samples showed a specific signal of all three 
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subunits at the appropriate molecular masses, starting at an imidazole concentration of 
80mM. The β3 specific antibody also stained degradation products. A [
3H]flunitrazepam 
binding assay of the same washing and elution samples indicated that most of the 
α1β3γ2His12 receptor was eluted during washing with 80mM imidazole. With this low 
amount of imidazole not only receptors but also a lot of other proteins were eluted from 
the column, which was seen in a Coomassie blue staining of the same samples. The 
double 6 His-tag (His12) on the γ2 subunit thus did not exhibit the expected strong 
binding to the Ni-NTA column, compared to a receptor with a His8-tag on the β3 
subunit, which exists twice in an α1β3γ2 receptor. Due to the 2 β3-His8 subunits, the 
α1β3His8γ2 GABAA receptor could be eluted with 200mM imidazole and therefore the 
eluted fractions exhibited a much higher purity. 
The low expression level and the β3 degradation led to the assumption that the 
β3 subunit was not expressed in the correct manner in the triple construct to form 
α1β3γ2 receptors in Sf9 cells. Thus further expression experiments were done with the 
triple construct and additional β3 viruses for the infection of Sf9 cells. [
3H]flunitrazepam 
binding indicated no enhancement in the expression of α1β3γ2 receptors in the 
membrane. The [3H]flunitrazepam binding reached the same level of 0.5pmol per mg 
total protein independent of increasing amounts of additional recombinant β3 viruses. A 
Western blot with subunit specific antibodies confirmed this result and indicated 
degradation for all three subunits. 
The degradation and the low expression level of the triple construct compared 
to the single viruses expressing α1β3His8γ2 GABAA receptors, could be caused by the 
different ratios of the transfected subunits. Sf9 cells were transfected with the ratios of 
2:1:1 and 3:1:1 to produce α1β3His8γ2 GABAA receptors whereas the ratio of the 
expressed triple construct subunits is not known. In the triple construct the expression 
of the α1 and the γ2 subunit was under the control of the p10 promoter, whereas the 
β3His8 subunit was under the control of the polh promoter. Both promoters could differ 
in promoter activity and time point of activation leading to problems during the 
assembly of functional GABAA receptors. 
Summarizing the results for the triple construct, we showed that we were able to 
clone all three subunits of a GABAA receptor into one vector and to produce 
recombinant baculoviruses that express very little, but functional receptors in Sf9 cells. 
The resulting receptors contain active GABA and benzodiazepine binding pockets. 
In summary, three different approaches were investigated for the production 
and purification of large amounts of α1β3γ2 GABAA receptors in this thesis. Experiments 
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indicated, that the first approach with α1, β3His8 and γ2 recombinant viruses and a 
two-step purification yielded the purest α1β3γ2 receptors, but only 3% of total receptors 
could be purified. We were able to express the receptor in the picomolar range, which 
can be used for further structural analysis, but not for crystallization. The other two 
approaches yielded expression levels around 0.5pmol receptor/mg total protein and we 
were not able to concentrate these receptors with the Ni-NTA column, thus showing, 
that a minimum of expressed receptors in the membrane is needed for purification. 
Nevertheless large scale expression of the α1, β3His8 and γ2 recombinant virus 
combination in Sf9 cells is currently performed for a different purpose. After purification, 
the receptor will be separated on a BlueNative(BN)/SDS-PAGE. The group of 
Professor Lubec, Vienna is going to pick spots from the gel, make an in-gel digestion 
and identify the proteins and their sequence with qQTOF. The sequence of the alpha1 
and the beta3 subunit has already been published with this method (Kang et al. 2008; 
Kang and Lubec 2009). This group therefore will concentrate on sequencing the 
gamma2 subunit. 
Knowing also the sequence of the gamma2 GABAA receptor subunit, it is 
planned to investigate drug-binding sites at the α1γ2 interface of these receptors 
identified by photoaffinity labeling of the receptors with suitable drugs. In addition, it is 
planned to investigate whether purified α1β3His8γ2 GABAA receptors could be used for 
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5 ABBREVIATIONS 
AcMNPV Autographa californica multiple nuclear polyhedrosis virus 
APS  Ammoniumpersulfate 
Bmax  Maximal binding site density 
BCA  Bicinchoninic acid 
BZ  Benzodiazepine 
CDS  Coding sequence 
CNS  Central nervous system 
DNA  Desoxyribonucleic acid 
DTT  Dithiothreitol 
Dpi  Days post infection 
EDTA  Ethylenediaminetetraacetic acid 
GABA  γ-Aminobutyric acid 
HEPES N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid 
KCl  Kaliumchlorid 
KD  Ligand concentration where 50% of all receptors are occupied 
kDa  Kilo Dalton 
MBP  Maltose binding protein 
Moi  Multiplicity of infection 
MOPS  N-Morpholino propanesulfonic acid 
Ni-NTA Nickel-Nitrilotriacidic acid 
PAGE  Polyacrylamide gel electrophoresis 
Pfu  Plaque forming unit 
PBS  Phosphate buffered saline 
PMSF  Phenylmethanesulfonylfluoride 
RNAse Ribonuclease 
RT  Room temperature 
SDS  Sodium dodecyl sulphate 
TEMED N,N,N´,N´-tetra-methyl-ethylene-diamine 
Tris  Tris (hydroxymethyl) aminoethane 
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9 SUMMARY / ZUSAMMENFASSUNG 
9.1 Summary 
The γ-aminobutyric acid (GABA) is the most abundant inhibitory 
neurotransmitter in the mammalian central nervous system. GABA acts via two 
different classes of receptors, the GABAA receptors, which are Cl
- channels that can be 
opened by GABA and the GABAB receptors, which are indirectly coupled to Ca
2+ and 
K+ channels via second messenger systems. GABAA receptors are composed of five 
subunits that can belong to eight different subunit classes. The majority of receptors 
are composed of two α, two β and one γ subunits. 
In addition to GABA, many drugs, such as benzodiazepines, barbiturates, 
steroids, anaesthetics, and convulsants, are able to bind to and thereby modulate the 
GABAA receptors. The exact molecular structure is still unknown, as it is the case for 
most receptors of the cys-loop receptor super-family. Aim of this thesis was to produce 
and purify large amounts of recombinant hetero-oligomeric (alpha1-beta3-gamma2) 
GABAA receptors for subsequent structural analysis, such as crystallization, photo 
affinity labeling or surface plasmon resonance investigations. 
For that, receptors with three different subunit compositions (α1β3His8γ2, 
α1β3γ2His8 and α1β3γ2His12) were expressed using the baculovirus expression system 
in Sf9 cells for large scale purification. The α1β3γ2His12 construct was cloned newly 
into a pBac4x-1 vector. After generating stable baculovirus stocks for all constructs, the 
best expression conditions were determined for each receptor type using [3H]muscimol 
and [3H]benzodiazepine binding studies. Degradation of the proteins was investigated 
by SDS-polyacrylamide gel electrophoresis, Coomassie blue staining and Western blot 
analysis. Purification of the receptors via their His tag using a Ni-NTA column (and a 
benzodiazepine containing affinity column for the α1β3His8γ2 construct) provided 
dissimilar results. In a two-step purification the α1β3His8γ2 receptor resulted in an 
estimated purity of 90% with little degradation of the subunits, but with a low yield. The 
α1β3γ2His8 and the α1β3γ2His12 receptors presented a reduced overall expression with 
degradation products of the subunits and thus the recovery was lower as for the 
α1β3His8γ2 receptor. Since a minimum of functional receptors in the membrane is 
needed for purification, the expressed α1β3His8γ2 construct with a two-step purification 
will be used for further structural analysis. 
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9.2 Zusammenfassung 
Die γ-Aminobuttersäure (GABA) ist die am häufigsten vorkommende 
inhibitorische Neurotransmitter-Substanz im zentralen Nervensystem von Säugetieren. 
GABA wirkt über zwei verschiedene Klassen von Rezeptoren, die GABAA-Rezeptoren, 
die Cl—Kanäle sind, welche durch GABA geöffnet werden können, und die GABAB-
Rezeptoren, die indirekt über second messenger systems an Ca2+- oder K+-Kanäle 
gekoppelt sind. GABAA-Rezeptoren bestehen aus fünf Untereinheiten, die acht 
verschiedenen Untereinheitsklassen angehören können. Die Mehrheit der Rezeptoren 
besteht aus zwei α, zwei β und einer γ Untereinheiten. 
Neben GABA können viele Wirkstoffe, wie Benzodiazepine, Barbiturate, 
Steroide, Anästhetika oder Konvulsiva, an GABAA-Rezeptoren binden und diese 
modulieren. Wie bei den meisten Rezeptoren der cys-loop receptor super-family, ist die 
genaue Struktur des GABAA-Rezeptors bis jetzt nicht bekannt. Ziel dieser Arbeit war 
die Produktion und Reinigung von großen Mengen rekombinanter hetero-oligomerer 
(alpha1-beta3-gamma2) GABAA-Rezeptoren, die anschließend mittels Kristallisations-
versuchen, photo affinity labeling oder surface plasmon resonance zur strukturellen 
Analyse verwendet werden sollten. 
Zu diesem Zweck wurden drei verschiedene Untereinheits-Kombinationen 
(α1β3His8γ2, α1β3γ2His8 und α1β3γ2His12) im Baculovirus Expressionssystem in Sf9 
Zellen exprimiert, um diese dann im großen Maßstab zu reinigen. Das α1β3γ2His12 
Konstrukt wurde neu in einen pBAC4x-1 Vektor kloniert. Nachdem stabile Virenstocks 
für alle Kombinationen erzeugt wurden, wurden die besten Expressionsbedingungen 
für jeden Rezeptortyp mittels [3H]Muscimol und [3H]Benzodiazepin Bindungsstudien 
bestimmt. Der Abbau der Proteine wurde mittels SDS-polyacrylamide gel 
electrophoresis, Coomassie blue staining und Western blot analysis untersucht. Die 
Reinigung der Rezeptoren über deren His-Tag mittels einer Ni-NTA Säule (und einer 
Benzodiazepin beinhaltenden Affinitätssäule für den α1β3His8γ2 Rezeptor) ergab 
unterschiedliche Ergebnisse. Mittels 2-Stufenreinigung konnte der α1β3His8γ2 Rezeptor 
mit einer geschätzten Reinheit von 90% und geringem Abbau der Untereinheiten, 
allerdings mit sehr geringer Ausbeute, gereinigt werden. Die α1β3γ2His8 und 
α1β3γ2His12 Rezeptoren zeigten eine verminderte Expression und Abbauprodukte und 
somit eine geringere Ausbeute der Konstrukte als beim α1β3His8γ2 Rezeptor. Da für 
eine Reinigung ein Minimum an intakten Rezeptoren in der Membran vorhanden sein 
muss, wird in Zukunft das α1β3His8γ2 Konstrukt mit einer 2-Stufenreinigung für weitere 
Strukturanalysen verwendet werden. 
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